University of Kentucky

UKnowledge
Theses and Dissertations--Physiology

Physiology

2013

NMDA RECEPTORS IN THE DORSAL VAGAL COMPLEX OF
NORMAL AND DIABETIC MICE
Eva C. Bach
University of Kentucky, ecbach2@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Bach, Eva C., "NMDA RECEPTORS IN THE DORSAL VAGAL COMPLEX OF NORMAL AND DIABETIC MICE"
(2013). Theses and Dissertations--Physiology. 14.
https://uknowledge.uky.edu/physiology_etds/14

This Doctoral Dissertation is brought to you for free and open access by the Physiology at UKnowledge. It has been
accepted for inclusion in Theses and Dissertations--Physiology by an authorized administrator of UKnowledge. For
more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained and attached hereto needed written
permission statements(s) from the owner(s) of each third-party copyrighted matter to be
included in my work, allowing electronic distribution (if such use is not permitted by the fair use
doctrine).
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive
and make accessible my work in whole or in part in all forms of media, now or hereafter known.
I agree that the document mentioned above may be made available immediately for worldwide
access unless a preapproved embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s dissertation
including all changes required by the advisory committee. The undersigned agree to abide by
the statements above.
Eva C. Bach, Student
Dr. Bret N. Smith, Major Professor
Dr. Bret N. Smith, Director of Graduate Studies

NMDA RECEPTORS IN THE DORSAL
VAGAL COMPLEX OF NORMAL AND DIABETIC MICE

DISSERTATION

A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
Department of Physiology in the College of Medicine
at the University of Kentucky
By
Eva Claudia Bach
Lexington, Kentucky

Director: Dr. Bret N. Smith, Professor of Physiology
Lexington, Kentucky
2013
Copyright© Eva Claudia Bach 2013

ABSTRACT OF DISSERTATION

NMDA RECEPTORS IN THE DORSAL
VAGAL COMPLEX OF NORMAL AND DIABETIC MICE

The dorsal vagal complex (DVC), containing the nucleus of the solitary
tract (NTS) and the dorsal motor nucleus of the vagus nerve (DMV), plays a
pivotal role in autonomic regulation. Afferent fibers from peripheral organs and
higher brain centers synapse in the NTS, which integrates these synaptic
connections as well as information from systemically circulating hormones and
metabolites. The integrated information is relayed to the dorsal motor nucleus of
the vagus nerve (DMV), which in turn, projects motor fibers to elicit
parasympathetic control of digestive and other viscera. Physiological functions
mediated by the DVC are disrupted in diabetic patients and synaptic plasticity
within the DVC has been linked to these complications. N-methyl-D-aspartic acid
(NMDA) receptors have been extensively studied for their involvement in
synaptic plasticity in a variety of central nervous system disorders; and their
activation in the DVC modulates hepatic glucose production and feeding
behavior. Although chronic disease can alter NMDA function, changes in DVC
expression and/or sensitivity of NMDA receptors in diabetic states has not been
addressed. Using whole cell electrophysiology, functional properties of the nuclei
in the DVC were investigated in normoglycemic and type 1 diabetic mice.
Preterminal NMDA (preNMDA) receptors were discovered to tonically modulate
excitatory neurotransmission on terminals contacting DMV neurons. While these
preNMDA receptors were not found to differentially modulate tonic excitatory
neurotranmission, soma-dendritic NMDA receptor responses of NTS neurons
were augmented in type 1 diabetic mice. Through the use single-cell PCR,
increased NMDA receptor responses could be correlated to neurons that mediate
excitatory neurotransmission and would argue that augmented NMDA receptor
responses increase vagal output. In general, enhancing vagal output decreases
activity of connected peripheral organs. Molecular approaches were employed to
corroborate the observed functional NMDA receptors changes to their protein
and mRNA expression levels. Overall, results argue that NMDA receptors are
involved in synaptic plasticity in DVC of type 1 diabetic mice to enhance
excitatory neurotransmission. This modulation may potentially serve as a

physiological counter regulatory mechanism to control pathological disturbances
of gastrointestinal homeostatic reflex responses.
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Chapter 1: Introduction

The Dorsal Vagal Complex
Circuit organization and neurotransmission in the Dorsal Vagal Complex

The dorsal vagal complex (DVC) of the caudal brainstem regulates central
parasympathetic reflex and integrative functions, including those of the digestive
system. Viscerosensory inputs mediated by cranial nerves VII, IX and X in
conjunction to centrally-originating afferents form synapses in the nucleus of the
solitary tract (NTS). The NTS consists of a heterogeneous population of cells,
which incorporates mechanical stimuli from peripheral organs as well as from
circulating hormones and metabolites, and transmits this information to other
autonomic centers including the dorsal motor nucleus of the vagus nerve (DMV)
(Browning and Travagli, 2011; Kalia and Mesulam, 1980a; Kalia and Mesulam,
1980b; Travagli, 2007; Travagli et al., 2006). The DMV contains preganglionic
motor neurons that project back to peripheral organs. As a unit, the fiber tracts,
the NTS, and the DMV mediate the vago-vagal reflex (Browning and Travagli,
2011; Kalia and Mesulam, 1980a; Kalia and Mesulam, 1980b; Travagli, 2007;
Travagli et al., 2006).
DMV neurons maintain tonic pacemaker activity (Travagli et al., 1991a).
This input, however, is tightly regulated by predominantly GABAergic and
glutamatergic presynaptic neurons of the NTS (Davis et al., 2004; Glatzer et al.,
1

2007; Travagli, 2012). GABAergic inputs maintain a tonic inhibitory drive that
dominates the regulation of vagal outflow, with glutamatergic inputs serving a
phasic excitatory role (Gao and Smith, 2010; Travagli et al., 1991b). An
enhanced excitatory drive to DMV neurons and subsequent increase of vagal
output would be expected to invoke stimulation of peripheral organs to aid in
maintaining appropriate energy homeostasis, and glucose homeostasis in
particular (Zsombok and Smith, 2009). Increased vagal outflow lowers hepatic
gluconeogenesis, enhances pancreatic exocrine function (i.e. release of insulin)
and stimulates gastric emptying (Ahren et al., 1996; Pocai et al., 2005b;
Saltzman and McCallum, 1983).
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Figure 1.1 Schematic of gastrointestinal reflex-arc of the brainstem.
DMV= Dorsal Motor Nucleus of the Vagus, NTS= Nucleus of the Solitary Tract

Energy homeostasis in the DVC and pathological consequences

Homeostatic gastric reflex responses are a good example of a response
mediated by the DVC that can be modulated by a complex array of peripheral as
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well as CNS signals (Barber and Burks, 1983; Barber and Burks, 1987; Travagli
et al., 2006). Furthermore, it exemplifies a response whose homoeostatic
imbalance can lead to pathological complications (Saltzman and McCallum,
1983). Gastric reflexes are in part controlled by mechanical as well as
chemoactivation. Therefore, when the stomach becomes full and consequently
experiences mechanical distension and chemoactivation of various satiety
signals, vagal afferents that synapse in the NTS become activated to trigger the
cessation of feeding (Barber and Burks, 1983; Barber and Burks, 1987; Travagli
et al., 2006). Synaptic inputs also arise from higher brain centers, notably the
hypothalamic nuclei, which provide additional signals related to the overall
metabolic status (Obici et al., 2002; Pocai et al., 2005a).
The collective input from these various signals, as well as those of
peripheral hormones and metabolites discussed below, help fine-tune
parasympathetic reflex responses of the gastrointestinal organs including the
stomach. It is, therefore, not surprising that incongruence between these
collective signals can result in pathological outcomes. In the context of the
stomach, gastroparesis has been well established as a pathological symptom of
diabetic patients (Saltzman and McCallum, 1983; Zsombok and Smith, 2009).
Diabetes mellitus is a metabolic disease of glucose characterized by the
body’s inability to maintain glucose homeostasis. This can arise either from
pancreatic β-cell islet destruction and the concomitant inability of the body to
synthesize insulin (Type 1 diabetes), or abnormal insulin secretion and insulin
resistance (Type 2 diabetes) (Zimmet et al., 2001).

4

Beyond synaptic inputs to the DVC, signaling the status of various
metabolic functions, fenestrated capillaries surrounding this region of the brain
provide a direct indication on the status of circulating hormones and metabolites
(Gross et al., 1990; Merchenthaler, 1991). Of particular interest is the ability of
this nucleus to directly respond to hormones and metabolites that mediate
glucose homeostasis. Glucose itself modulates efferent activity of the DVC
through subpopulation of cells in the NTS and the DMV that respond to changing
glucose concentrations by altering their firing properties. These glucose-sensitive
neurons respond to both hypoglycemic as well as hyperglycemic conditions to
elicit vagal efferent responses conducive to maintaining and reestablishing
glucose homeostasis (Babic et al., 2012; Balfour et al., 2006; Balfour and Trapp,
2007; Browning and Travagli, 2010; Ferreira et al., 2001; Pocai et al., 2005b).
In conjunction with glucose, other metabolites that have been well
established for their peripheral role in glucose homeostasis have a direct effect
on neurons within the DVC. A few of these hormonal players include insulin,
leptin and glucagon-like peptide-1 (GLP-1). In particular, insulin as well as leptin
modulate synaptic input to the DMV and on NTS neurons through the activation
of insulin and leptin receptors, respectively, that results in a decrease of
glutamate release on gastric related neurons. Both were shown to act in a PI3Kdependent mechanism suggesting their activation of signaling cascades similar
to those observed in peripheral organs and hypothalamic nuclei (Blake and
Smith, 2012; Williams and Smith, 2006; Williams et al., 2007). GLP-1 activity has
been shown to enhance both the excitatory and inhibitory activity to pancreatic-
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projecting neurons in the DMV (Wan et al., 2007). Collectively the direct effects
of metabolites and hormones at the level of the DVC, suggests that they are
important players in minute to minute efferent output modulation.
The complexity of the synaptic rules governing homeostatic
gastrointestinal reflex responses elicited by the DVC emphasizes the need to
better understand these principles and how they can be modulated under
physiological as well as pathological circumstances. A more comprehensive
understanding of their mechanisms may serve as a potential tool to manipulate
glucose homeostasis and prevent symptoms of diabetic patients. As a result,
studying the DVC in the context of diabetes has garnered increased attention in
the global epidemic of metabolic disorders (Zsombok and Smith, 2009).
The role of the CNS in the diabetes epidemic
Diabetes, in particular Type 2 diabetes, is emerging as one of the most
prevalent diseases of the developed world (Zimmet et al., 2001). Due to its
effects on peripheral organs that modulate hormone homeostasis, diabetes has
classically been treated as a peripheral disease, but the pathological involvement
of the CNS has garnered increased attention more recently when various studies
linked changes neuronal responses and synaptic reorganization of central
nervous system (CNS) to glucose dysregulation and diabetes (Levin et al., 1999;
Obici et al., 2002; Zsombok and Smith, 2009).
To begin to understand the effects diabetes has on synaptic connections
of the DVC, the streptozotocin (STZ) model of Type 1 diabetes (T1-diabetes) was
used in electrophysiological studies in the DMV. This model involves injecting
6

animals systemically with STZ, which kills the insulin-producing pancreatic β-cells
and causing chronic hyperglycemia in conjunction with hypoinsulemia
(Craighead, 1980). These studies revealed that DMV neurons of diabetic animals
receive enhanced excitatory input. More specifically, this study revealed an
increase in the spontaneous and miniature excitatory postsynaptic current
(sEPSC and mEPSC) frequency in DMV neurons of T1-diabetic mice. No change
phasic in spontaneous or miniature inhibitory post synaptic currents (sIPSCs or
mIPSCs) was observed in these studies and suggested modulation specific to
excitatory neurotransmission in T1-diabetic mice (Zsombok et al., 2011). An
increase in the EPSC frequency suggests an increase in the probability of
glutamate release presynaptically, from the presynaptic terminal and/or from
presynaptic neurons. Glutamate is the principal excitatory neurotransmitter in the
DVC and activates both NMDA and non-NMDA receptors (Bonham and Hasser,
1993; Seagard et al., 1999; Smith et al., 2002).

NMDA Receptors
Function and Pharmacology of NMDA Receptors
NMDA receptors are ionotropic receptors prominently thought to consist
as tetrameric subunit assemblies (Paoletti and Neyton, 2007; Traynelis et al.,
2010). Upon activation by glutamate and/or glycine, NMDA receptors typically
contribute to cellular depolarization and Ca2+-dependent signaling cascades by
increasing the conductance of Na+ and Ca2+. Under normal physiological
conditions the presence of Mg2+, and its permeation into the pore of the channel,
7

leads to a block of ionic flux (Mayer et al., 1984; Nowak et al., 1984). Both the
extent of Mg2+ inhibition and Ca2+ permeation, however, are dependent on the
subunit assembly of NMDA receptors (Traynelis et al., 2010).
Throughout the CNS seven NMDA receptor subunits have been identified,
namely NR1, NR2A-D and NR3A/B subunits. While NR1 subunit incorporation is
thought to be obligatory to form functional receptors, these subunits are not
believed to assemble as homomers. Rather it is thought that NMDA receptors
exist in a di- or tri-heteromeric state, but it is still unclear whether NR3 subunits
are able to assemble with NR1 subunits in the absence of NR2 subunits (Paoletti
and Neyton, 2007; Traynelis et al., 2010). This may be due to the functional
significance of NR2 subunits have in assembly (Meddows et al., 2001).
Each subunit is composed of four domains, an N-terminal domain (NTD),
an agonist binding domain (ABD), a transmembrane domain (TMD) and a Cterminus domain (CTD). The NTD is most critically involved in subunit assembly
and contains the binding site for the allosteric NR2A-subunits inhibitor Zn2+ , as
well as the allosteric NR2B-subunit inhibitor Ro-25-698, an ifenprodil-like
compound (Meddows et al., 2001). The ABD binds the agonist glycine on NR1and NR3-subunits and glutamate on NR2-subunits
Additionally, this domain binds competitive antagonists such as 2-amino-5phosphonopentanoic acid (AP-5) (Paoletti and Neyton, 2007). The TMD lines the
pore region of NMDA receptors where Mg2+ and channel blockers such as
dizocilpine (MK-801) permeate to block channel conductance. Finally, the CTD is
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located intracellularly and is important in protein interactions (Paoletti and
Neyton, 2007).
As mentioned above, NMDA receptor subunit assemblies alter the
pharmacokinetics of NMDA receptors (Paoletti and Neyton, 2007; Traynelis et
al., 2010). NR2-subunit types, in particular, have a ~50 fold range of decay times
in the order NR2A< NR2B<NR2C<NR2D, with decay time constants of
NR1/NR2D lasting between 4-5 seconds (Cull-Candy and Leszkiewicz, 2004).
Furthermore, Mg2+ sensitivities differ amongst the subunits and correlate with
Ca2+ permeability and channel conductance. Consequently, NR2A/B subunits
have higher conductance states and Ca2+ permeability, but show much higher
Mg2+ sensitivity than NR2C and NR2D subunit containing receptors. While it
remains unclear whether or not NR3 subunits form functional channels in the
absence of NR2 subunits, expression systems have identified these receptors to
lack Mg2+ sensitivity and are virtually impermeable to Ca2+ (Henson et al., 2010;
Pachernegg et al., 2012).

NMDA receptor subunit regional and developmental expression profiles
Subunit distribution is both regionally and developmentally regulated.
Being obligatory to functional NMDA receptors, the NR1 subunit is expressed
throughout the brain at all stages of development. During early development,
NR2B subunits are the primary subunits expressed throughout all brain regions,
but its high level of expression is maintained only the forebrain areas throughout
adulthood. NR2A receptor expression, on the other hand, progressively
9

increases to high levels of ubiquitous expression. The expression profiles of
these subunits are established by postnatal day (P) 21 and are maintained into
adulthood. NR2C and NR2D have a more restricted expression pattern. NR2C
subunit expression increases at P7 into adulthood, but its strongly expressed
only in the cerebellum. While NR2D expression occurs throughout the brain,
expression drops dramatically throughout development and during adulthood
remains limited to the brainstem and diencepehlon (Lujan et al., 2005; Monyer et
al., 1994; Paoletti, 2011). NR3A subunit expression has been quite contradictory
and may be region specific. In most nuclei studied to date, expression increases
markedly to peak between P4-P10, when expression decreases again to a low
level adult expression, although notably in the amygdala peak expression seems
to occur in adult mice (Henson et al., 2010; Wong et al., 2002). NR3B subunits
on the other hand progressively increase their expression, which they maintain
throughout adulthood, and virtually everywhere in the CNS (Henson et al., 2010;
Paoletti, 2011; Wee et al., 2008). Some of these expression changes have been
shown to correlate with critical periods in development of the central nervous
system. It has therefore been proposed that the differences in kinetic properties
of the receptor subunits aid in establishing and maintaining neuronal circuits
during early development and into adulthood, respectively (Paoletti P, Zhou,
2013). Neuronal activity patterns are thought to be a crucial determinant in these
processes (Bellone and Nicoll, 2007). As a result, subunit expression changes
have been studied in various disorders of the CNS, and such changes have been
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identified in a wide array of diseases including diabetes (Di Luca et al., 1999; Lau
and Zukin, 2007; Paoletti et al., 2013).
NMDA receptors in the context of synaptic plasticity
Synaptic plasticity is the process by which the central nervous system
establishes and refines the circuitry between nuclei of the brain. Long-term
potentiation (LTP) and long term depression (LTD), to strengthen and weaken
synaptic contacts respectively, are two of the most widely studied mechanisms of
synaptic plasticity (Bliss and Lomo, 1973; Citri and Malenka, 2008). These
mechanisms are thought to underlie learning and memory processes (Bliss and
Lomo, 1973).
Experimentally, high frequency stimulation (HFS) or pairing protocols were
recognized to trigger the induction of LTP, while prolonged low frequency
stimulation resulted in the induction of LTD. Both of these mechanisms were
prevented through the inhibition of NMDA receptors (Collingridge et al., 1983;
Dudek and Bear, 1992). The realization that both of these mechanisms, resulting
in opposing levels of synaptic strength, were NMDA dependent intensified the
search for the underlying mechanisms. It became apparent that NMDA receptors
act as coincidence detectors as a result of their unique biophysical properties
dependent on both ligand and voltage dependent gating. Consequently, a robust
presynaptic stimulation, and concomitant glutamate release, is needed to
activate postsynaptic α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors and produce membrane depolarization conducive to Mg2+
expulsion from the pore of NMDA receptors. Permeation of Ca2+ through Ca2+
11

permeable NMDA receptors were subsequently shown to underlie signaling
mechanism essential to LTP and LTD. The Ca2+ concentrations and the temporal
profile of Ca2+ flux is believed to underlie the reason distinct signaling pathways
favoring either LTP or LTD are activated (Malenka et al., 1989). Whereas LTP
requires Ca2+ flux above a critical threshold, LTD is triggered by a modest influx
of Ca2+ (Cummings et al., 1996; Malenka and Nicoll, 1993). One of the
established signaling molecules involved in triggering LTP is the
Calcium/calmodulin (CaM)-dependent protein kinase II (CaMKII) (Barria et al.,
1997; Fukunaga et al., 1995). The prominent opinion of LTD induction holds that
it is dependent on phosphatase activity including that of calcineurin,
subsequently acting on the protein kinase A and C (PKA and PKC) (Hrabetova
and Sacktor, 1996; Kameyama et al., 1998; Lisman, 1989)
In LTP, these signaling cascades potentiate the insertion of AMPA
receptors and their subunits into the postsynaptic density (PSD). The insertion
and/or subunit exchange of AMPA receptors into the postsynaptic density can
lead to both the strengthening and unsilencing of synaptic contacts (Durand et
al., 1996; Malenka and Nicoll, 1997). As a result, the cell can respond more
robustly to presynaptically released glutamate (Benke et al., 1998; Citri and
Malenka, 2008). LTP induced AMPA insertion into the PSD is believed to occur
within one hour of LTP induction, but LTP is also thought to initiate more long
term changes that lead to the restructuring and stabilization of the newly
organized synapse (Reymann and Frey, 2007; Thomas and Huganir, 2004). In
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LTD, AMPA receptor removal leads to an overall weakening of the synapse (Citri
and Malenka, 2008).
NMDA receptor-dependent receptor trafficking has established itself as an
important process in synaptic plasticity. Receptor localization in relation to the
PSD, and in effect presynaptic release sites, plays an important role in the level
of glutamate available for binding. Synaptic receptors opposing the presynaptic
terminal directly receive glutamate released preteriminally and consequently are
more readily activated. Perisynaptic receptors are located just outside the PSD
and are generally thought to be activated as a result of glutamate spillover from
the PSD due to increased excitatory neurotransmission. The role of extrasynaptic
NMDA receptors remains controversial. One argument is that they may serve as
receptor reserve pools and aid in the trafficking of AMPA receptors. Additionally,
other studies have identified that these receptors respond to ambient glutamate
outside and maintain a tonic NMDA current (Lau and Zukin, 2007; SanzClemente et al., 2013).
While NMDA receptors play a crucial role in synaptic plasticity during
development, pathological insults can lead to dysfunctional NMDA receptor
subunit expression, trafficking and localization. The disruption of these processes
has been demonstrated in a wide array of pathologies including pain, Alzheimer’s
disease, Parkinson’s disease and depression as well as diabetes (Artola et al.,
2005; Paoletti et al., 2013). Long-term diabetes is associated with cognitive
impairments as well as abnormalities in brain structure and their activation
(Artola, 2008).
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The link between cognitive decline and memory formation in the
hippocampus spawned an interest in studying the effect diabetes and the ability
to induce mechanism of synaptic plasticity such as LTP and LTD (Artola, 2008).
Using the streptozotocin (STZ) model of Type 1 diabetes (T1-diabetes), it was
originally thought that prolonged hyperglycemia may nearly abolish the ability to
induce HFS or pairing dependent LTP while producing larger LFS dependent
LTD (Chabot et al., 1997; Kamal et al., 1999). More recently, additional studies
have revealed that both LTP and LTD are of comparable magnitude in T1diabetic animals, but that the membrane threshold for their induction is shifted
leftward in LTP and rightward in LTD (Artola et al., 2005). In this model the
subunit composition of NMDA receptors has been shown to be altered along with
expression of CaMKII (Di Luca et al., 1999). Overall, these studies provide
compelling evidence that disruption in energy homeostasis can have profound
influences on synaptic circuitry.
A large body of literature comes from the study of LTP and LTD in
hippocampal circuits where the original studies into their mechanisms were
conducted, but both forms of long-term synaptic plasticity have been identified in
many other regions of the brain (Citri and Malenka, 2008). Additionally, nonNMDA dependent forms of long term synaptic plasticity, in particular
metabotropic glutamate receptor (mGLUR) and endocanabanoid-mediated LTD
(eCB-LTD) have been identified throughout the brain (Bolshakov et al., 1997;
Gerdeman et al., 2002; Oliet et al., 1997). Studies of eCB-LTD identified a close
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link between endocannabonoid and NMDA signaling, including presynaptically
mediated mechanisms (Sjostrom et al., 2003).
Presynaptic NMDA Receptors
While NMDA receptors have classically been implicated in their
involvement of postsynaptic membrane depolarization, their presence and
significance on presynaptic terminal membranes has begun to emerge more
recently. The first evidence of preterminal NMDA (preNMDA) came from
immunohistochemical approaches that identified NMDA protein expression
patterns consistent with their localization on the preterminal membrane in the
hippocampus (Aoki et al., 1994). Following this discovery, their functional
significance as facilitators of glutamate release at hippocompal synapses was
established (Berretta and Jones, 1996). A newly found appreciation for NMDA
receptors at the preterminal membrane spawned an interest in their functional
significance in other regions of the CNS, which quickly lead to the identification in
a number of other nuclei, including the visual cortex and spinal cord (Glitsch and
Marty, 1999; Sjostrom et al., 2003). To date, NR2A, NR2B as well as NR3
subunits have been identified to be present on preNMDA receptors in various
regions of the brain (Bidoret et al., 2009; Casado et al., 2002; Larsen et al., 2011;
Yang et al., 2006). Some of these studies revealed that preNMDA receptors also
act as heteroreceptors by facilitating the release of GABA (Glitsch and Marty,
1999).
In cerebellar nuclei, preterminal depolarizations can result from voltagegated calcium channel activation elicited through electrotonic spread of NMDA15

mediated dendritic depolarization (Christie and Jahr, 2008), suggesting that
postsynaptic NMDA receptor activation can elicit effects on presynaptic
terminals. This view, however, is challenged not only by electrophysiological
evidence but by light and electron microscopic imaging studies localizing NMDA
receptors to axon terminals in several forebrain regions (Aoki et al., 1992; Aoki et
al., 1994; Bidoret et al., 2009; Charton et al., 1999; Woodhall et al., 2001; Yang
et al., 2006; Zhang et al., 2009).
Neurotransmitter release is Ca2+ dependent and short term facilitation is
thought to be the result of residual Ca2+ that remains bound to release sites (Katz
and Miledi, 1968, Kamiya, Zucker RS 1998, Bertram 1997). The hypothesis that
the increase of preterminal Ca2+ through the influx of Ca2+-permeable preNMDA
receptors was experimentally confirmed by Chochilla and Alford (1999). These
results have been expanded upon to show indirect activation through local
depolarizations that open voltage-gated Ca2+ channels and potentiation of Ca2+dependent Ca2+ release via ryanodine receptors (Lanore et al., 2010).
As the functional significance of preNMDA receptors became solidified,
their involvement in synaptic plasticity during development and in the context of
pathological states was investigated. Not long after their discovery their
involvement in epilepsy was identified, mediating an NR2B increase in the tonic
facilitation of glutamate (Yang et al., 2006). NR3-subunit containing receptors
established themselves as crucial players in developmental processes of the
visual cortex while preNMDA mediate LTD induction in the cerebellum and
neocortex (Casado et al., 2002; Larsen et al., 2011).
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NMDA receptor and their physiological significance in the DVC
In the brainstem all of the known NMDA receptor subunits (except NR3As)
have been shown to exist and undergo developmental expression pattern similar
to those seen elsewhere in the brain (Liu and Wong-Riley, 2010). On a
physiological level, NMDA receptors in the DVC have been linked to a variety of
gastrointestinal responses. Specifically activation of NMDA receptors through the
injection of NMDA or glycine, via bilateral guide cannulas implanted in the DVC,
resulted in a decrease of gluconeogenesis (Lam et al., 2010). This agonist
response could be inhibited though with NMDA receptor antagonists or
vagotomy. Using this approach it was further identified that activation of NMDA
receptors is necessary to process hypothalamically initiated signals to lower
gluconeogenesis (Lam et al., 2011; Lam et al., 2010). Inhibition of NMDA
receptors has also been shown to prevent the food intake reduction normally
elicited by hormones such as cholecystokinin (Wright et al., 2011). These studies
demonstrate the critical role NMDA receptors play in modulating energy
homeostasis in the DVC and questions what role they play under pathological
insults such as diabetes.
Glutamatargic neurons and their identification
The NTS is composed of a heterogeneous population of neurons, with
inhibitory GABAergic and excitatory glutamatergic neurons as the two
predominant populations (Lin and Talman, 2006; Travagli et al., 1991a).
Vesicular release of glutamate requires vesicular glutamate transporters
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(VGLUTs) that use a H+ electrochemical gradient to transport glutamate from the
cytoplasm into presynaptic vesicles (Santos et al., 2009). To date, three VGLUT
isoforms, VGLUT 1-3, have been identified (Herzog et al., 2001; Herzog et al.,
2004; Werner et al., 1998). These proteins differ in their localization throughout
the central nervous system. For instance, in the NTS both VGLUT2 and VGLUT3
show significant expression in neurons and do not appear to co-localize (Lin et
al., 2004; Lin and Talman, 2005). VGLUT1 expression is observed on afferent
terminals and sub regions of the NTS, but its expression is much lower (Hermes
et al., 2013; Lin, 2009) The expression of VLGUTs has been widely used as a
marker for glutamatergic neurons (El Mestikawy et al., 2011; Fremeau et al.,
2004; Santos et al., 2009). In the context of these studies VGLUTs are important
for phenotypic identification of glutamatergic neurons.
Study Aims and Significance
Metabolic disorders, diabetes in particular, are posing an unprecedented
societal burden throughout the developing world. The involvement and
pathological effects on the central nervous system are becoming increasingly
well established. The mechanisms underlying changes in the synaptic circuitry
within the CNS of diabetics are only beginning to be elucidated; and it remains
unclear whether or not these changes are reversible.
The DVC plays a critical role in energy metabolism, and has thus become
a region of interest in the involvement in the development of metabolic disorders.
Studies in this laboratory were previously conducted in STZ-induced T1-diabetic
mice and revealed an increased excitatory drive to DMV neurons (Zsombok
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2011). This study revealed that under conditions of chronic hyperglycemia and/or
hypoinsulemia DMV neurons are hyperexcited. The previously observed increase
in mEPSC and sEPSC frequency suggests that changes mediating
hyperexcitability occurrs presynaptic to DMV neurons.
Presynaptically released glutamate activates AMPA- and NMDAreceptors on the postsynaptic membrane. A change in the frequency of EPSCs,
in the absence of a change in amplitude, whole cell currents and/or decay time,
is indicative of a presynaptic change of glutamate release. Presynaptic changes
in glutamate release could be the result of changes in the number of synaptic
contacts and/or changes in the probability of glutamate release.
Increases in sEPSCs target mechanisms to changes at the somadendritic and/or presynaptic terminal membrane of presynaptic neurons.
Miniature excitatory post synaptic currents (mEPSCs) are action potential
independent events dependent on the stochastic release of glutamate release
(Kandel et al., 2000). The observed increase in mEPSC frequency in diabetic
mice suggests that synaptic plasticity that changes the are at least in part due to
changes occurring at terminals contacting DMV neurons.
NMDA receptors play an important role in glucose homeostasis in the
DVC and are amongst the most widely studied receptors in the context of
synaptic plasticity throughout the central nervous system (Lam et al., 2011;
Traynelis et al., 2010). Thus, they are likely candidates to show functional
modulation and contribute to the enhanced excitatory neurotransmission of the
DMV in T1-diabetic mice.
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Although preNMDA receptors and their involvement in mechanisms
underlying physiological and pathological changes in synaptic plasticity have
been identified in other regions of the CNS, their presence and functional
significance to synaptic circuitry have never been explored in the DVC. Chapter 3
of this dissertation was aimed at identifying the presence and functional
significance of preNMDA receptors on terminal contacts of DMV neurons.
Chapter 4 of this dissertation focuses on NMDA receptors in the DVC of
T1-diabetic mice. The increase in sEPSC frequency in diabetic mice suggested
that presynaptic neurons alter their function to enhance action potential
dependent release. NTS neurons form functional glutamatergic connections with
the DMV; and excitability in these neurons could trigger an increase in the
release of glutamate. It was hypothesized that NMDA receptors are unregulated
in presynaptic NTS neurons of T1-diabetic mice. Given that excitatory
neurotransmission was altered in T1-diabetic mice, it was hypothesized that
NMDA receptors were upregulated, particularly in the glutamatergic
subpopulation of neurons. This hypothesis was tested by using single-cell PCR
approaches to correlate NMDA-mediated electrophysiological responses to a
glutamatergic phenotype (VGLUT2+ neurons).
The studies conducted throughout this dissertation were aimed at
advancing the understanding of the rules governing neuronal excitatory,
transmission between nuclei of the DVC and their ability to undergo synaptic
plasticity in a model of T1-diabetes. An increase in this excitatory efferent output
could serve as counter-regulatory mechanism to lower gluconeogenesis in
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response excessive glucose concentrations induced by diabetes. Understanding
the mechanisms involved in this process could eventually pave the road to
developing therapeutic strategies for pathological perturbations of diabetes and
other metabolic disorders.
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Chapter 2: Materials and Methods

Animal Injections and monitoring
Adult (3-12 weeks) female and male CD-1 (Harlan Laboratories) or GIN
mice (FVB-Tg (GadGFP) 4570Swn/J; The Jackson Laboratory) were used for all
experiments. Experiments in Chapter 3 investigating the presence and functional
significance of preNMDA receptors on terminal contacts to DMV neurons were
conducted in male CD-1 mice exclusively. Experiments in Chapter 4 and 5
investigated changes in T1-diabetic mice also used both male and female GIN
mice. The effects on T1-diabetic mice were observed specifically on excitatory
neurotransmission presynaptic to DMV neurons. Consequently, mechanistic
changes were hypothesized to occur in presynaptic glutamatergic neurons. A
mouse strain expressing a fluorescent tag in glutamatergic neurons was
unavailable to target recordings specifically to the glutamatergic NTS neuronal
population. The best of alternative was to use the FVB-Tg (GadGFP) 4570Swn/J
to prevent recording from the somatostatin expressing GABA neuron population.
These neurons make up a large population of cells in the NTS and preventing
recordings from this population increased the probability of recording from a
glutamatergic neuron. As part of the studies conducted in Chapter 4 a
glutamatergic phenotype was confirmed using single-cell PCR (see RNA
isolation and Taq-Man PCR description). All animals were treated and cared for
in accordance with National Institutes of Health guidelines, and all procedures
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were approved by the Institutional Animal Care and Use Committee of the
University of Kentucky.
Intra-peritoneal injections of 200mg/kg (either a single dose or in 5 doses
of 40 mg/kg each over 5 days) of streptozotocin dissolved in saline (0.9% NaCl)
were performed on normoglycemic mice. Prior to injections and/or fasting (saline
injected animals were fasted for 4-6 hours) plasma glucose concentrations were
measured using a Nova Max® PLUS glucometer. Based on the limitations of the
glucometer, glucose levels could only be quantitatively determined up until blood
glucose levels of 600 mg/dl and higher blood glucose concentrations were
reported by the glucometer as high. The glucose levels table for diabetic animals
(see appendix 2), therefore, are semiquantitative averages that designated all
reading of high as 600 mg/dl and reported averages presumably are
underestimations of the true average. Before and following fasting mice were
provided food without restriction. Blood samples were obtained via tail prick and
blood glucose measurements from saline and streptozotocin injected animals
were taken daily until streptozotocin injected mice reached blood glucose levels
of 300 mg/dL or above for at least three days. Mice with blood glucose levels of
300 mg/dL were considered T1-diabetic mice and animals that maintained
hyperglycemic states for a minimum of 7 and up to 10 days were used for
electrophysiological and molecular studies. Saline injected animals were never
observed to reach blood glucose levels consistent with this level of
hyperglycemia. The final glucose measurements were taken on the day mice
were used sacrificed for experimental aims (animal treatments are outlined in
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Table 1 of the Appendix). The weight of all mice was monitored and animals
were excluded from further experiments if their weight dropped by more than
20% of their original body weight.
Brain stem slice preparation
Whole cell patch-clamp recordings were made using brainstem slices
prepared from mice. Mice were deeply anesthetized by halothane inhalation to
effect and then decapitated. The brain was removed and blocked on an ice-cold
stand and the brainstem was glued to a sectioning stage using a small amount of
crazy-glue® on a vibrating microtome (Vibratome Series 1000; Technical
Products, St. Louis, MO). The entire brainstem was fully covered with ice-cold
artificial cerebrospinal fluid (ACSF). Slices (300 µM) were cut at low vibrating
microtome speed but high cutting amplitude. Transverse (i.e. coronal) brain stem
slices (300 μm) from about 300 µm rostral to AP to the caudal edge of AP
containing the DVC were made in cold (0–2°C), oxygenated (95% O2-5% CO2)
ACSF using a vibrating microtome (Vibratome Series 1000; Technical Products,
St. Louis, MO). The ACSF contained (in mM): 124 NaCl, 3 KCl, 2 CaCl2, 1.3
MgCl2, 1.4 NaH2PO4, 26 NaHCO3, 11 glucose (pH 7.2–7.4; osmolality 290–315
mOsm/kg). Slices were then incubated for ≥1 h in warm (32–35°C) oxygenated
ACSF.
Electrophysiological Recordings
For recording, a single brain slice was transferred to a chamber mounted
on a fixed stage under an upright microscope (Model BX51WI; Olympus, Melville,
NY), where it was continually superfused with warmed oxygenated ACSF.
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Experimental drugs were added to perfusate via a pump. Prior to drug
application the time to reach the bath chamber was measured in order to more
accurately assess the time of drug activation.
Whole-cell voltage-clamp recordings were obtained in the DMV or NTS
using recording pipettes pulled from borosilicate glass (open tip resistance of 3–5
MΩ; King Precision Glass Co., Claremont, CA). The pipette solution for most
recordings contained (in mM): 130–140 Cs-gluconate , 10 HEPES, 1 NaCl, 1
CaCl2, 3 CsOH, 5 EGTA, and 2 Mg2+-ATP. Intracellular Cs+ was used as the
primary cation carrier in voltage-clamp recordings to block K+ currents, including
GABAB receptor-mediated currents in the recorded neuron. Neurons were
targeted for recording under a 40x water-immersion objective (numerical aperture
= 0.8) with infrared-differential interference contrast (IR-DIC).
Electrophysiological signals were obtained using a Axopatch 200B or Multiclamp
700B amplifier (Molecular Devices, Union City, CA), low-pass filtered at 2 or 3
kHz, digitized and recorded onto a computer (Digidata 1440A, Molecular
Devices) using pClamp 10.2 or 10.3 software (Molecular Devices). Seal
resistance was typically 2–5 GΩ and series resistance, measured from brief
voltage steps applied through the recording pipette (5 mV, 5 ms), was typically
<25 MΩ and monitored periodically during the recording. Recordings were
discarded if series resistance changed by >20% over the course of the
experiment.
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Electrical stimulation
Electrical stimulation was performed using a platinum-iridium concentric
bipolar electrode (125 μm diameter, FHC, Bowdoinham, ME) placed in the
medial NTS (Browning and Travagli, 2009; Glatzer et al., 2007). A minimum of 15
paired current pulses (2–100 μA; 300 μs; A.M.P.I., Jerusalem, Israel) at
interpulse intervals of 30 ms and a cycle rate of 0.1 Hz were administered to the
NTS, and responses in DMV neurons voltage-clamped at −80 mV were recorded
and analyzed for current amplitudes before, during, and after the application of
AP-5. The ratio of the second to the first response was measured to assess
changes of paired-pulse ratios (PPr) in response to AP-5. Paired-pulse ratios can
give an indication of the release probabilities of neurotransmitter release.
Changes in PPr are indicative of a change in presynaptic release properties, with
an increase in the ratio correlating to a decrease in the release probability
(Debanne et al., 1996; Dobrunz et al., 1997; Dobrunz and Stevens, 1997). In
connections in the DVC arising from the NTS and projecting to the DMV a paired
pulse depression, consistent with high release probabilities, has been observed
at inter-stimulus- intervals of 30-40 ms (Browning and Travagli, 2003; Williams et
al., 2007). To measure current responses at membrane potential between -110
to +30 mV, voltage steps were applied at 10 mV increments. Steps were of 1
second duration to reach maximal current responses for each voltage measured.
Incremental current step were made at inter-step-intervals of 400 ms. Current
measurement were averages of four runs and were measured at each potential
at the end of the voltage step. A current-voltage response graphs was
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extrapolated from these measurements and compared between control and T1diabetic mice.
Drugs used for electrophysiological recordings
The drugs and their respective concentrations, used for experiments were:
Tetrodotoxin (TTX; 1-2 µM; Alomone Labs) DL-2-Amino-5-phosphonopentanoic
acid (AP-5; 100 µM, Sigma), N-methyl-D-aspartic acid (NMDA; 15 µM; Sigma),
Ro 25-6981 (1 μM; Tocris), ZnCl2 (5 μM; MP Biomedicals), (-)-Bicuculline
methiodide (Bic; 30 µM; Sigma) or picrotoxin (PTX; 100 µM, Sigma) dtubocurarine chloride (DTC 10-20 μM; Sigma), Strychnine (1-2 µM; Tocris), Org
24598 (10 µM; Tocris), ALX-1393 (0.5 µM, Tocris), Glycine (30 µM,100 µM,300
µM,1000 µM, Fisher), 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10 µM,
Sigma), -(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
hydrogen maleate (MK-801; 1mM, Sigma) and Bumetanide (10-20 µM; Tocris).
RNA isolation
Two to three brainstem slices (300-600 μm) were isolated as described for
electrophysiological recordings. The DVC was carefully excised and tissue
sample and suspended in 400-500 µL of TRIzol® and gently shaken periodically
for 5-25 min. 100-250 µl of chloroform was added the tubes vortexed for 15 sec
and maintained at 4ºC for 20 min or incubate them 2-3 min at RT and
subsequently centrifuged at 12,000 rpm for 10-15 min at 4ºC. RNA supernatant
was transferred into fresh 1.5 ml centrifuge tubes and suspended in 500 µL of
ice-cold propanol. Resuspended samples were incubated at room temperature
for 10 minutes and subsequently centrifuged at 12,000 rpm for 10 min at 4ºC.
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Propanol was decanted and RNA was washed by resuspension in 500 µL 75%
EtOH followed by centrifugation at 7500-12,000 rpm for 10 min at 4ºC. This
wash step was repeated, the EtOH decanted. RNA samples were air-dried for
10-20 min. RNA samples were resuspended in 8-10 µL RNAse-free water and
stored at -80 ºC or immediately reverse transcribed into cDNA. When obtaining
single-cell mRNA the cytosol of the cell was aspirated into the recording pipette
The recording pipette carefully pulled away from the cell and its contents were
expelled into a sterile centrifuge tube. RNA was stored at -80 ºC or immediately
reverse transcribed into cDNA.
TaqMan PCR
RNA samples were reverse transcribed in Reverse-Transcription Master
Mix (1 µl random nonamers (50 uM) (Sigma), 5 µl MMLV RT buffer (5x) (Fisher),
5 µl dNTPs (10 mM) (ThermoScientific), 2 µl DEPC-treated H2O (Fisher), 1 µl
Reverse Transcriptase (Fisher), and 1 µl RNAse Inhibitor (Fisher). For single-cell
RT-PCR experiments, the cytosol was aspirated following electrophysiological
recordings and suspended in RNA Reverse-Transcription Master Mix without
enzymes and stored at -80 ºC until further use. Groups of cells were reverse
transcribed after the addition of 1 µl Reverse Transcriptase (Fisher), and 1 µl
RNAse Inhibitor (Fisher) in a thermocycler (Eppendorf Mastercycler) at 42ºC for
90 min followed by 5 min at 95ºC. For phenotype identification, positive controls
(tissue samples) and single cells were probed for the presence of β-actin and
VGLUT2. Primers and probes for β-actin were: fwd,
CAGCAGGTACAGCATCACGG; rev, GCCATGTACGTAGCCATCC; probe,
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CTGGTCGTACCACAGGCATTGTG; for VGLUT2: fwd,
CCCGTCTACGCGATAATTGTT; rev, GTCATGACAAGGTGAGGGACT; Probe,
ACTGCTCATCAGCCAGCTT and for GAD67: fwd,
CCGTTCTTAGCTGGAAGCAG; rev, GTCTTGTGAGCGCCTTCAG; Probe,
CCGGCGCACAGAGACCGACTTCT.
Mastermix containing 3 µl (β-actin) or 2 µl (VGLUT2) MgCl2 (25 mM), 2.4 µl PCR
buffer (10x), 1 µl dNTPs (10 mM), 1 µl primers/probe (10 uM), 0.5 DNA
polymerase and 14 µl was prepared and 3 µl of single cell or positive control
RNA or RNAse free sterile H2O (non-template control) loaded into optical tubes
or a 96-well plate (Bio Rad). Samples were centrifuged for 2 min at 1000 RPM
and placed in an ABI-Thermocylcer for PCR analysis. Samples were held at 95
ºC 2 min and cycled 50 times at 95 ºC for 30 s, 60 ºC for 15 s and at 72º C 15 s.
NanoString
To measure quantitative changes in mRNA expression between control
and T1-diabetic mice, the NanoString® nCounter® system was used. The
NanoString technology bridges the gap between measuring a few to a few
dozens of genes using traditional qPCR and genome wide microarray studies by
allowing the analysis of up to 800 genes. The multiplex capability of this
technology allows genes to be assayed in a single reaction with as little as 100
ng of total RNA (Geiss et al., 2008; Kulkarni, 2011). The sensitivity achieved
using the NanoString matches that of TaqMan based PCR and surpasses
microarray sensitivity. NanoString does not require enzymatic amplification steps
which can introduce experimental bias (Geiss et al., 2008; Malkov et al., 2009).
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Sequences are detected though the use of 2 sequence specific probes (reporter
and capture probe) for each gene detecting a total of around 100 contiguous
base-pairs. The reporter probe carries a six-tiered barcode of non-overlapping
fluorescent colors, each assigned to a gene of interest. RNA samples are mixed
together with buffers and an excess of probes and the reaction is fully automated
from this point forward. In short, the initial step allows the hybridization of probes
to target sequences. Next, the capture probe, with its biotin labeled 3’ end
facilitates the capture and immobilization to streptavidin-coated slides. The
excess probes are washed away and the color codes are counted (Kulkarni,
2011). More recently the technology has been adapted to allow detection at the
single cell level and samples from paraffin embedded samples. To achieve a
single cell detection sensitivity of 10 pg of total RNA an additional enzymatic
amplification of RNA (Multiplexed Target Enrichment) step is added to the overall
procedure.
A custom designed codeset was designed by and purchased from
NanoString technologies (for complete list see Appendix 4). This codeset
included the seven known NMDA receptor subunits (NR1, NR2A-D and NR3A-B)
as well as four housekeeping genes (beta-actin, GAPDH, Hprt1, Ubc). The
isolated RNA quality assessment and concentration determination was made at
the University of Kentucky using the Agilent's Bioanalyzer 2100. The average
RNA integrity number (RIN) for samples used in this study were 9.4 ± 0.07
(Range: 8.9-9.7). 100 ng of total RNA was used from each sample. Hybridization
reaction using the custom designed codeset, and nCounter® master mix, was
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performed according to protocol by the microarray facility at the University of
Kentucky using the nCounter® from NanaString® Technology. The NanoSting
probe identifiers for genes analyzed throughout this dissertation were: For NR1:
NM_008169.2:492, for NR2A: NM_008170.2:4080, for NR2B:
NM_008171.3:6340, for NR2C: NM_010350.2:2720, for NR2D:
NM_008172.2:1201, for NR3A: NM_001033351.1:1332, for NR3B:
NM_130455.2:2030, for beta-actin: NM_007393.3:1138, for GAPDH:
NM_001001303.1:890, for Hprt1: NM_013556.2:30, for Ubc: NM_019639.4:21.
For a more complete list of probes included in these analyses refer to Appendix
2. Normalization was performed using the nSolver™ software from NanoString®
Technology. The nSolver® software normalizes to negative and positive controls
to eliminate background noise and variability unrelated to samples. To calculate
the normalization factor of these controls the geometric mean (geometric mean=
𝑛

√𝑥1 𝑥 2 … 𝑥 𝑛 ) of each sample is obtained. Subsequently, to account for variability

between samples the geometic mean of samples is taken. This average is
divided by individual sample specific geometric means to calculate a

normalization factor, which is multiplied by sample specific counts. Normalization
of endogenous control genes, is subsequently conducted, on counts normalized
to positive and negative controls using the same workflow of normalization used
for positive and negative controls.
Western Blots
Brainstem slices (300-600 μm) were isolated as described for
electrophysiological recordings. The DVC was isolated and sections were
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immediately transferred to 40-60 µl of lysis buffer consisting of 0.15M NaCl, 5mM
EDTA (pH 8), 1% Triton X-100, 10mM Tris-Hcl (pH 7.4), 10ul/ml of 100mM
PMSF (174.2 mg/10ml in methanol), and 100ul/ml of 0.5M NaF (pH 10). Each
sample was sonicated and centrifuged immediately at 12,000 RPM for 3 min.
Supernatant was aspirated, aliquoted, and stored at -80 ºC until further use.
Protein concentration was measured using a Bradford Protein Assay. For
Western blots, 20 µg of protein was loaded per lane. The appropriate volume of
sample together with equal amounts of loading buffer were boiled in water for 2
min. Samples and ladder were loaded into precast PDF gels in and subsequently
the gel was electrophoresed at 50 mA for 45–80 min. Proteins were then
transferred at 200 mA for 2 hrs onto polyvinylidene difluoride membranes for
Western blot analysis. Membranes were blocked in 1:1 Odyssey blocking
buffer/PBS/0.1% Tween 20 for 1 hr at room temperature. Due to well separated
molecular weights of the NR1 (band at 105-120 kD) and β-actin (band at 40-45
kD) protein membranes could be cut in half to be incubated over-night at 4°C,
with a rabbit monoclonal anti-NMDAR1 (1:1000; Abcam) and a rabbit monoclonal
anti-β-actin (1:10000; Abcam) antibody in Odyssey blocking buffer/PBS/0.1%
Tween 20. Membranes were washed with 4 times 5 min with PBS on a shaker.
After the final wash membranes were scanned on a densitometer (Odyssey
model 9120, Li-COR Biosciences) to quantify band density. Background density
was subtracted from the NMDAR1 band density and normalized to β-actin, which
was used as a loading control.
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Statistical analysis
For electrophysiological recordings, an n was defined as an individual
neuron that was recorded from. For some of the experimental groups within this
dissertation, multiple neurons where recorded from a single animal. In all
experimental groups at least three animals were used to validate that the
observed responses were not due to an abnormal animal’s response. The
glycine transport inhibitor study of T1-diabetic mice is an exception. Since studies
of potential preterminal glycine and NR3-subunit containing NMDA receptors
were not completed the glycine transport inhibitor study was halted and included
only two mice for preliminary results presented in this dissertation.
Spontaneous and miniature postsynaptic currents (PSCs) were analyzed
with MiniAnalysis (Synaptosoft) to measure the peak amplitude, frequency, and
decay time. Spontaneous or miniature synaptic events (minimum 65; typically 2min continuous recording) were measured within a recording under each
condition. Intra-assay analysis of drug-evoked changes in spontaneous and
miniature PSC frequency and amplitude within a recording were assessed using
a Kolmogorov-Smirnov test.
For electrical simulations, evoked responses were analyzed using
pClamp. Peak amplitudes from a minimum of 15 evoked responses were
averaged and measured for each treatment. To attain a paired-pulse response
ratio, the ratio of the amplitude of the second to the first EPSC response to
afferent stimulation was calculated. The primary effect was on the first amplitude
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and paired-pulse recordings were therefore normalized to the amplitude of the
second response.
Pooled results of single comparisons of drug effects (i.e., before and after
a single drug treatment) were analyzed using a paired, two-tailed Student’s t-test.
When comparing pooled effects of a single variable between two animal groups
(comparison between untreated controls or saline injected controls and
streptozotocin injected mice) a homoscedastic two-tailed Student’s t-test was
used. In studies between animals, in which a variable based on a drug response
was introduced, a two-way Anova was employed to test for statistical
significance. Identifying percent changes as a function of drug application
consolidated frequency responses into a single variable and a two-tailed
homoscedastic Student’s t-test could therefore be used to compare responses
between animal groups. The nature of responses through western blot analysis
and paired-pulse ratios did not produce normally distributed responses.
As a result, a non-parametric Wilcoxon signed-rank test was, therefore, used to
test for statistical significance.
Statistical significance for all measures was set at P < 0.05. Statistical
measurements were performed with Microsoft Excel (Microsoft, Redmond, WA)
or Prism (GraphPad Software, La Jolla, CA). Numbers were expressed as means
± SE.
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Chapter 3- Presynaptic NMDA receptor-mediated modulation of excitatory
neurotransmission in the mouse dorsal motor nucleus of the vagus

Introduction
Studies conducted in this chapter were aimed at gaining a better
understanding of the circuitry within the DVC; more specifically presynaptic
modulation of excitatory and inhibitory neurotransmission on terminals contacting
DMV neurons.
While NMDA receptors typically contribute to postsynaptic conductances,
their role as presynaptic receptors that modulate neurotransmitter release from
synaptic terminals is receiving increased attention, and various subunit
combinations have been identified at preterminal receptors (Corlew et al., 2008;
Engelman and MacDermott, 2004; Ma and Hargreaves, 2000; MacDermott et al.,
1999). Presynaptic glutamate receptors, possibly including NMDA receptors,
contribute to glutamatergic heterosynaptic facilitation of GABA release onto DMV
neurons (Derbenev et al., 2006), but the sub-type of glutamate receptor
mediating this enhanced release is not known. Metabotropic glutamate receptors
have been identified previously to contribute to modulation of both excitatory and
inhibitory neurotransmission in the DMV (Browning and Travagli, 2007).
These findings are consistent with the hypothesis that glutamate released
in the DMV can regulate synaptic transmission by acting at receptors on afferent
terminals. Presynaptic NMDA receptors, and their potential role in contributing to
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facilitation of fast excitatory and/or inhibitory neurotransmission have not been
adequately studied in the DVC.
This study aimed to identify the presence of presynaptic NMDA receptors
in the DMV and their functional relevance as modulators of excitatory and/or
inhibitory neurotransmission.
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Figure 3. 1 Schematic representation of preNMDA mediated facilitation of
neurotransmitter release of NTS terminals contacting DMV neurons.
Methods
Only methods and materials specific to this Chapter are restated here. To avoid
redundancy refer to Chapter 2 of this dissertation, when indicated.

Animals
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Male CD-1 mice (Harlan, Indianapolis, IN), 4–11 wk of age, were housed under a
standard 14-h light 10-h dark cycle, with food and water provided without
restriction. All animals were treated and cared for in accordance with National
Institutes of Health guidelines and all procedures were approved by the
Institutional Animal Care and Use Committee of the University of Kentucky.

Brain stem slice preparation- see general methods in Chapter 2

Electrophysiological recording- see general methods in Chapter 2 for complete
methods. Seal resistance was typically 2–5 GΩ and series resistance, measured
from brief voltage steps applied through the recording pipette (5 mV, 5 ms), was
typically <25 MΩ (mean=13.03±0.86 MΩ) and monitored periodically during the
recording. Recordings were discarded if series resistance changed by >20% over
the course of the experiment.

Drugs used for electrophysiological recording- For specific experiments, DL-2Amino-5-phosphonopentanoic acid (AP-5; 100 µM), N-methyl-D-aspartic acid
(NMDA; 15 µM), Ro 25-6981 (1 μM), ZnCl2 (5 μM), or picrotoxin (PTX; 100 µM;
Sigma, Ellisville, MO) were added to ACSF. When indicated, -(+)-5-Methyl-10,11dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801; 1
mM) was added to the pipette solution to block postsynaptic NMDA receptors in
the recorded cell. Inadvertent ejection of MK-801 during acquisition of patchclamp recordings was unavoidable, and such leakage could result in inconsistent
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blockade of receptors. Such blockade was predicted to affect responses to low
levels of glutamate released endogenously in the slice, so MK-801 was added to
the recording pipette for agonist application experiments only. Intracellular Cs+
was used as the primary cation carrier in voltage-clamp recordings to block K+
currents, including GABAB receptor-mediated currents in the recorded neuron.

Electrical Stimulation- Electrical stimulation was performed using a platinumiridium concentric bipolar electrode (125 µm diameter, FHC, Bowdoinham, ME)
placed in the medial NTS (Browning and Travagli, 2009; Glatzer et al., 2007). A
minimum of 15 paired current pulses (2–100 µA; 300 µs; A.M.P.I., Jerusalem,
Israel) at inter-pulse intervals of 30 ms and a cycle rate of 0.1 Hz were
administered to the NTS and responses in DMV neurons voltage-clamped at -80
mV were recorded and analyzed for current amplitudes before, during, and after
the application of AP-5.

Data analysis - For electrical stimulation, peak amplitudes from a minimum of 15
evoked responses were averaged and measured for each treatment using
pClamp programs and analyzed using a paired, two-tailed Student’s t-test.
Paired-pulse response ratios, taken as the ratio of the amplitude of the second to
the first EPSC response to afferent stimulation resulted in non-normal
disctributed ratios. Based on the fact that these ratios incorporated two normally
distributed populations of amplitudes (first and second amplitude) a non-
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parametric statistical was deemed appropriate. Ratios were analyzed using a
non-parametric Wilcoxon signed-rank test.
Results
Blocking NMDA receptors decreased tonic excitatory input to DMV neurons
Electrophysiological recordings were made in voltage-clamp mode in the
presence of PTX (100 µM) and TTX (1-2 µM) using Cs+ intracellularly to block K+
currents. At a membrane potential of -80 mV, postsynaptic NMDA receptors in
DMV neurons are under substantial voltage-dependent Mg2+ blockade, reducing
the contribution to EPSCs of NMDA receptor activation. By also blocking fast
IPSCs with PTX, action potential propagation with TTX, and K+ channels with
intracellular Cs+, the effect of the NMDA receptor antagonist AP-5 was targeted
to presynaptic effects of glutamate release acting on AMPA mediated mEPSCs.
Bath application of AP-5 (100 µM) resulted in an average 31.1 ± 5.7% decrease
in mEPSC frequency (n=9), from a baseline frequency of 12.4 ± 3.6 events/s to
8.3±2.5 events/s in AP-5 (p<0.05; Fig. 3.2). Application of AP-5 did not result in a
significant change in amplitude (19.8 ± 1.8 pA baseline; 19.2±1.5 pA AP-5;
p=0.21) or decay time constant (1.6 ± 0.1 ms baseline; 1.6 ± 0.9 ms AP-5;
p=0.43) of mEPSCs. The decrease in mEPSC frequency in response to AP-5, in
the absence of a change in amplitude or decay time, suggested that AP-5
inhibited glutamate release by acting at receptors located on presynaptic
terminals.
In cortical neurons, NMDA receptors located on presynaptic terminals
have been reported to contain NR2B subunits (Woodhall et al., 2001; Yang et al.,
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2006). To test the hypothesis that NR2B-containing receptors modulated
glutamate release in the DMV, the NR2B antagonist Ro 25-6981 (1 µM) was
applied under conditions identical to those used for AP-5 experiments. No
change was observed in frequency (14.5 ± 2.9 events/s baseline; 16.8 ± 3.7
events/s Ro 25-6981; p=0.10; n=11), amplitude (19.5 ± 1.8 pA baseline; 17.4 ±
2.3 pA Ro 25-698; p=0.28) or decay time (1.8 ms baseline; 2.0 ms Ro 25-6981;
p=0.06; Fig. 2). Since NR2A subunit-containing NMDA receptors have also been
identified at presynaptic terminals (Bidoret et al., 2009), we tested for the
presence of this subunit using ZnCl2. Application of ZnCl2 (5 µM) resulted in a
significant decrease in mEPSC frequency from 15.5 ± 2.9 events/s to 11.6 ± 2.2
events/s in the presence of ZnCl2 (n=8; p<0.05). No change in amplitude (19.6 ±
1.6 pA baseline; 20.0 ± 2.3 pA ZnCl2; p=0.48) or decay time constant (1.7 ± 0.2
ms baseline; 1.8 ± 0.2 ms ZnCl2; p= 0.45) was observed (Fig. 3.3.)
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Figure 3. 2 Blockade of NMDA receptors decreased mEPSC frequency without
changing amplitude or decay time constant.
A. Representative recording of mEPSCs in a DMV neuron. B. Recording of
mEPSCs from the same neuron during the application of AP-5 (100 µM; 10 min
application). C. Recording from the same neuron during wash of control ACSF
(i.e., no AP-5). Boxed areas in A-C are shown expanded temporally below each
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trace. D. Cumulative probability plots of mEPSC frequency, amplitude, and decay
time constant for the neuron represented in A-C. E. Mean mEPSC frequency,
amplitude and decay time constant before and during the application of AP-5
(n=9; asterisk indicates significant difference from control established through the
use of a paired two-tailed Student’s t-test; p<0.05).
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Figure 3. 3 Application of Ro 25-6981 did not change frequency, amplitude or
decay time of mEPSC, while ZnCl2 application decreased mEPSC frequency
without changing amplitude or decay time constant.
A. Representative recording of mEPSCs in a DMV neuron. B. Recording of
mEPSCs from the same neuron during the application of ZnCl2 (5 µM; 15 min
application). C. Recording from the same neuron during wash to control ACSF.
Boxed areas in A-C are shown expanded temporally below each trace. D.
Cumulative probability plots of mEPSC frequency, amplitude, and decay time
constant for the neuron represented in A-C. E. Mean mEPSC frequency,
amplitude and decay time constant before and during the application of ZnCl2
(n=8) or Ro 25-6981 (1 µM; n=11); asterisk indicates significant difference from
control using a paired two-tailed Student’s t-test; p<0.05.
NMDA facilitates glutamatergic release onto DMV neurons
When bath applying the receptor agonist NMDA at the previously
described concentration of 15µM, MK-801 was included in the intracellular
solution in order to permeate and block postsynaptic NMDA receptors from within
the cell (Berretta and Jones, 1996; Glitsch and Marty, 1999). Neurons were first
depolarized to 0 mV for 5 min to facilitate blockade of the receptor pore (Berretta
and Jones, 1996). Following this initial depolarization, the membrane was
repolarized to a holding potential of -80 mV for recording EPSCs in the presence
of PTX and TTX. Consistent with the MK-801 blockade of postsynaptic NMDA
receptors, application of NMDA (15 µM) did not induce a significant changes to
whole cell holding currents in response to AP-5 (-3.0± 5.1 pA in response to
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NMDA), nor was mEPSC amplitude (20.0± 2.0 pA baseline; 20.1 ± 2.1 pA
NMDA; p=0.87) or decay time (1.8± 0.2 ms baseline; 1.7± 0.2 ms NMDA;
p=0.70) altered (Fig. 3.4). However, NMDA application resulted in a significant
increase in mEPSC frequency (27±4.7%), from 10.8 ± 2.9 events/s before and
14.4 ±3.3 events/s during NMDA application (n=6; p<0.05; Fig. 3). The increase
in mEPSC frequency in absence of a change in whole-cell current or mEPSC
amplitude or decay time constant implied that NMDA augmented glutamate
release by acting at presynaptic terminals.
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Figure 3. 4 NMDA application increased mEPSC frequency without changing
amplitude or decay time.
A. Representative recording of mEPSCs in a DMV cell in control ACSF. B.
Recording of mEPSCs during the application of NMDA (10 µM). Boxed areas in
A and B are shown expanded below each trace. C. Cumulative probability plots
of mEPSC frequency, amplitude, and decay time constant for the cell
represented in A and B. D. Average mEPSC frequency, amplitude, and decay
time constant before and during the application of NMDA (n=6; asterisk indicates
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significant difference from control using a paired two-tailed Student’s t-test;
p<0.05). Pipette solution contained MK-801 (1 mM).
Electrical stimulation
Paired electrical stimuli (30ms interstimulus interval) were delivered to the
NTS at 0.1 Hz and resulting paired evoked EPSC (eEPSC) amplitudes were
recorded in DMV neurons in the presence of picrotoxin at -80 mV. Paired
stimulation of the NTS resulted in eEPSCs that typically displayed prominent
paired pulse depression of the second response. The average amplitude of the
first eEPSC was significantly decreased following application of AP-5 (90 ± 10pA
baseline; 51 ± 6 pA AP-5; p<0.05), without a significant change in the amplitude
of the second response (61 ± 6 pA baseline; 53 ± 5 pA AP-5; p=0.29; Fig. 3.5).
This greater relative effect on the first EPSC amplitude resulted in a decrease in
paired-pulse depression, which was reflected in an increase in the paired-pulse
ratio (PPr; 0.7 ± 0.1 baseline and 1.2 ± 0.3 in the presence of AP-5; n=9;
p<0.05). The change in PPr induced by AP-5 was consistent with activity at
receptors located on presynaptic terminals and suggested a reduction in the
ongoing activity of endogenously activated NMDA receptors.
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Figure 3. 5 NMDA receptor blockade induced a decrease in the amplitude of
EPSCs evoked after NTS stimulation and an increase in PPr.
A. Paired electrical stimulation of the NTS in control ACSF, AP-5 (100 µM), and
15 min after removal of the antagonist indicated in a decrease in evoked EPSC
amplitude during drug application. Averages of 15 responses are shown for each
condition. B. Averaged evoked EPSCs (normalized to the amplitude of the
second response in A) before, during, and after the application of AP-5 indicated
the antagonist induced a greater decrease in the first response amplitude than
the second. C. Mean paired-pulse ratio for control, AP-5, and wash indicates a
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significant increase in PPr using a Wilcoxon signed-rank test (P>0.05; n=9). D.
The PPr of individual cells shows the increase in PPr by AP-5 application in 8 out
of 9 cells tested.
NMDA receptor modulation did not affect IPSCs
Activation of ionotropic glutamate receptors enhances GABA release from
synaptic terminals in the DMV (Derbenev et al., 2006). The hypothesis that
presynaptic NMDA receptor activation increases GABA release was tested by
recording mIPSCs in voltage clamp mode at a holding potential of 0 mV in the
presence of TTX and intracellular Cs+. The mean mIPSC frequency (1.0 ± 0.3
events/s baseline; 1.0 ± 0.3 events/s NMDA; p=0.94), amplitude (26.1 ± 1.7 pA
baseline; 25.2 ± 2.7 pA NMDA; p=0.95), and decay time constant (7.0 ± 0.6 ms
baseline; 7.3 ± 0.6 ms NMDA; p=0.50) were not changed following the
application of NMDA (15µM; n=7; 3.6.). Likewise, blockade of NMDA receptors
with AP-5 (100 µM; n=7) did not alter mIPSC frequency (2.9 ±0.8 events/s
baseline; 2.2 ± 0.8 events/s AP-5; p=0.922), amplitude (30.6 ± 2.7 pA baseline;
31.6 ± 3.2 pA AP-5; p=0.97), or decay time constant (8.6 ±0.7 ms baseline; 8.5
±0.6 ms AP-5; p=0.94; Fig 3.7.). These results suggested that activation or
blockade of NMDA receptors on GABA terminals did not consistently alter
synaptic GABA release onto DMV neurons.
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Figure 3. 6 Effect of NMDA application on mIPSCs was not significant.
A. Representative baseline recording of mIPSCs. B. Recoding of mIPSCs in the
presence of NMDA (15 µM). C. Average frequency, amplitude, and decay time
constant of mIPSCs in response to NMDA indicated no significant mean changes
using a paired two-tailed Student’s t-test (P>0.05; n=7). Pipette solution
contained MK-801 (1 mM).
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Figure 3. 7 NMDA receptor blockade was without effect on mIPSCs.
A. Representative baseline recording of mIPSCs. B. Representative recordings
of mIPSCs in the presence of AP-5 (100 µM). C. Average frequency, amplitude
and decay time constant of mIPSCs in response to AP-5 indicated no significant
mean changes using a paired two-tailed Student’s t-test (P>0.05; n=7).
Discussion
A goal of this study was to provide evidence supporting the presence and
function of NMDA receptors on presynaptic terminals contacting DMV neurons in
the DVC. In other brain regions, including the hippocampus and the neocortex,
presynaptic NMDA receptors have been found to function as autoreceptors to
facilitate the release of glutamate (Berretta and Jones, 1996; Brasier and
Feldman, 2008), participating in increasing excitatory synaptic tone (Woodhall et
al., 2001). Presynaptic NMDA receptors located on GABAergic terminals have
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also been found to function as heteroreceptors to enhance the release of GABA
(Duguid and Smart, 2004; Mathew and Hablitz, 2011; Sjostrom et al., 2003).
Given these disparate functions of presynaptic NMDA receptors and the existing
evidence for glutamatergic modulation of GABA release in the DVC (Browning
and Travagli, 2007; Derbenev et al., 2006), this study was further aimed at
identifying their putative function on synaptic activity in the DVC. Effects of
NMDA receptor activation and antagonism on mEPSCs and paired evoked
responses to afferent stimulation were consistent with the presence of NMDA
receptors on glutamate terminals in the DMV.
A change in the frequency of action potential-independent (miniature)
synaptic currents, in the absence of a change in the amplitude or decay time
constant, suggests an NMDA receptor-mediated modulation of neurotransmitter
release from presynaptic terminals. The decrease in mEPSC frequency in
response to AP-5 or Zn2+, in the absence of a change in mEPSC decay time
constant or amplitude, suggests that presynaptic NMDA receptors are activated
by ambient glutamate and tonically facilitate excitatory input to DMV neurons.
Further, the increase in mEPSC frequency in response to applied NMDA
suggests that the receptors are not fully saturated in the slice preparation.
Consequently, an increase in presynaptic activity resulting in an increase in
preterimal glutamate release could be maintained through preNMDA
autoreceptors responses. Physiologically, preNMDA autoreceptors may therefore
act as important mediators to facilitate spacio-temporal integration of disparate
incoming inputs.
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ZnCl2 application resulted in a decrease in mEPSC frequency similar to
that of AP-5, while the selective NR2B subunit containing receptor antagonist Ro
25-6981 failed to have an effect on parameters measured. While it remains
possible that other subunits, are also present, these data suggest that NMDA
receptors on glutamatergic presynaptic terminals in the DMV most likely contain
NR2A, but not NR2B subunits, in young adult mice. NR2B and NR1 subunitcontaining NMDA receptors are present at birth, but there is a progressive
inclusion of NR2A subunits in the first 3-5 weeks of life, after which expression
stabilizes (Quinlan et al., 1999; Sheng et al., 1994). Although relative subunit
expression may influence NMDA receptor expression differently in immature
animals, most animals used in the present study were >5 weeks of age, a time at
which NMDA receptor expression is relatively stable.
Blockade of NMDA receptors can reduce the fidelity of synaptic currents
evoked subsequent to stimulation of the NTS, and the change in PPr further
suggests this occurs subsequent to modulation of NMDA receptors located on
presynaptic terminals. The paired-pulse depression observed here and
previously (Browning and Travagli, 2003; Browning and Travagli, 2009; Glatzer
and Smith, 2005; Williams et al., 2007) suggests a synaptic connection with
relatively high release probability, with the second response being of smalleramplitude due to depletion of the readily-releasable primed pool during the first
activated release (Debanne et al., 1996). A change in the PPr is often interpreted
to indicate preterminal modulation of neurotransmitter release probability, with an
increase in the ratio implicating a decrease in the probability of release (Debanne
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et al., 1996; Dobrunz et al., 1997; Dobrunz and Stevens, 1997). Modulation of
the amplitude of the first evoked EPSC by NMDA receptor blockade suggests
that presynaptic NMDA receptors modulate terminal Ca2+ influx tonically. The
absence of change in the second amplitude may imply that successive stimuli
activate additional Ca2+-permeable receptors, allowing further release of the
available vesicular pool.
Tonic activation of presynaptic NMDA receptors to enhance excitatory
synaptic input has been suggested in other regions of the brain (Berretta and
Jones, 1996; Sjostrom et al., 2003). This autoreceptor-mediated facilitation may
serve to enhance the overall gain of the glutamate response at particular
synapse locations. As such, presynaptic NMDA receptor modulation could
selectively enhance specific signals, for example those arriving from the NTS, as
opposed to those arriving from other central areas. In the DMV, satiety signals
from diencephalic brain areas converge with inputs arising from NTS neurons
relaying specific mechanical or chemical visceral signals pertaining to
physiological state, especially from digestive system organs. Modulation of feedforward glutamate tone via presynaptic NMDA receptors would be expected to
increase the gain at active synapses, contributing to both temporal and spatial
integration of synaptic signals in the DMV. In effect, appropriately timed central
and peripheral satiety signals could thus augment each other by affecting
summated glutamate release along specific physiologically relevant synaptic
pathways driving central parasympathetic output.
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In addition to enhancing glutamate release, presynaptic NMDA receptors
have also been found to enhance GABA release in some regions of the brain
(Duguid and Smart, 2004; Glitsch and Marty, 1999; Mathew and Hablitz, 2011),
and glutamate enhances GABA release in the DMV by acting at ionotropic and
metabotropic receptors on presynaptic GABA terminals (Derbenev et al., 2006).
GABA neurons are prominent in the medial NTS, which project inhibitory inputs
to gastrointestinal-projecting regions of the DMV (Davis et al., 2004; Derbenev et
al., 2004; Ferreira et al., 2001; Glatzer et al., 2007; Travagli RA, 1991). Inhibitory
input to DMV cells has been found to be modulated through a variety of
preterminal receptors, including those for monoamines, catecholamines,
peptides, and lipids, in addition to glutamate receptors on GABA terminals
(Browning and Travagli, 2007; Derbenev et al., 2006; Glatzer et al., 2007;
Travagli and Gillis, 1995; Zsombok et al., 2011). Metabotropic glutamate
receptors have been found to serve a complex integrative role to maintain both
tonic tone of inhibitory neurotransmission and negatively modulate acitivitydependent excitatory neurotransmission in synaptic connections between NTS
and DMV neurons (Browning and Travagli, 2007). Failure to observe a consistent
change in mIPSC frequency in response to NMDA or AP-5 suggests that the
glutamatergic heteroreceptors participating in the response of DMV neurons to
TRPV1 activation (Derbenev et al., 2006) are likely not predominantly NMDA
receptors. It further suggests that glutamatergic terminals with presynaptic NMDA
receptors are not in close proximity to heteroreceptors, since the increased
glutamate released by presynaptic NMDA receptor activation might be expected
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to “spill over” and activate glutamate heteroreceptors on GABA terminals, and
consequently increase mIPSC frequency. This was not the case. It remains
possible that presynaptic NMDA receptors exist on a subset of GABA terminals,
but the absence of any predominant effect on GABA release suggests that
presynaptic NMDA receptors are located preferentially on glutamatergic
terminals, most likely including those arising from NTS afferents. Thus,
activation of presynaptic NMDA autoreceptors may represent a spatially distinct
means of selectively augmenting glutamate release in the DMV.
In cerebellar nuclei, preterminal depolarizations can result from voltagegated calcium channel activation elicited through electrotonic spread of NMDAmediated dendritic depolarization (Christie and Jahr, 2008), suggesting that
postsynaptic NMDA receptor activation can elicit effects on presynaptic
terminals. This view, however, is challenged not only by electrophysiological
evidence but by light and electron microscopic imaging studies localizing NMDA
receptors to axon terminals in several forebrain regions (Aoki et al., 1992; Aoki et
al., 1994; Bidoret et al., 2009; Charton et al., 1999; Woodhall et al., 2001; Yang
et al., 2006; Zhang et al., 2009). The present results are consistent with the
hypothesis that NMDA receptors located at presynaptic terminals regulate
synaptic glutamate release in the DMV, since NMDA effects on mEPSCs
persisted when the postsynaptic channels were blocked from inside the cell.
However, the possibility that NMDA receptors located on dendrites contribute to
presynatic modulation via a retrograde signal (e.g., electrotonic depolarization)
remains to be explored. In summary, the results obtained in this study suggest
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that NMDA receptors are present on presynaptic terminals and their activation
positively modulates glutamate release onto DMV neurons, with little effect on
GABA release. The presence of presynaptic NMDA receptors on GABAergic
terminals cannot be entirely excluded, but if present their physiological function
relative to synaptic regulation of DMV neurons is unclear. Presynaptic NMDA
receptors on glutamate terminals facilitate the release of glutamate tonically,
providing a means of downregulating as well as upregulating glutamate release,
depending on ongoing synaptic activity. Their activation may serve to augment
specific excitatory synaptic contacts in an autoregulatory fashion, acting to
enhance specific inputs in a spatially and temporally distinct manner.
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Chapter 4: NMDA receptor modulation of excitatory neurotransmission in
the dorsal vagal complex of Type 1 Diabetic mice

Introduction
Chapter 3 of this dissertation established the presence and function of
NMDA receptors on terminals contacting DMV neurons to tonically facilitate the
release of glutamate, but not GABA, onto this nucleus (Bach and Smith, 2012).
Activating NMDA receptors in the DVC results in decreased
gluconeogenesis, while their inhibition suppresses food intake (Lam et al., 2011;
Ritter, 2011). NMDA receptor function in the DVC is, therefore, critical for
homeostatic regulation of vagal activity and visceral function. Synaptic input to
DMV neurons is altered in disease states affecting visceral function,
underscoring the importance of understanding synaptic control of these neurons
(Zsombok et al., 2011). A tonic elevation in glutamate release was observed
previously in the DMV of T1-diabetic mice (Zsombok et al., 2011; Zsombok and
Smith, 2009), suggesting a chronic alteration in synaptic regulation of vagal
activity. The mechanism/s of this modulation remains to be elucidated. NMDA
receptors have been extensively studied for their involvement in modulating
synaptic plasticity under physiologic as well as pathologic states.
Changes in NMDA sensitivity in central vagal circuits could contribute to
elevated glutamate release in the DVC and subsequent modulation of visceral
function associated with diabetes. The hypothesis that plasticity of NMDA
receptor function in the DVC of T1-diabetic mice leads to the observed increase
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in excitatory neurotransmission was tested. Figure 4.1 shows a schematic
illustration of the potential sites of NMDA receptor modulation.
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Figure 4.1 Schematic illustration of potential sites of presynaptic NMDA receptor
modulation to enhance excitatory neurotransmission to DMV neuron of T1diabetic mice.
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Material and Methods
Animals
Male and female mice CD-1 (Harlan, Indianapolis, IN) and GIN mice (FVB-Tg
(GadGFP) 4570Swn/J; The Jackson Laboratory) 4–11 wk of age, were housed
under a standard 14-h light/10 h dark cycle, with food and water provided without
restriction. All animals were treated and cared for in accordance with National
Institutes of Health guidelines and all procedures were approved by the
Institutional Animal Care and Use Committee of the University of Kentucky.

Animal Injections
Mice were given intra-peritoneal injections of 200mg/kg (either a single dose or in
5 doses of 40 mg/kg each over 5 days) of streptozotocin. Controls were either
injected with saline (0.9% NaCl) or untreated. No differences in
electrophysiological parameters were observed between normoglycemic salineinjected and untreated mice. They were therefore pooled and considered as a
single control group. Systemic glucose levels were measured prior to injections
and monitored daily. Animals were used for electrophysiological recordings and
molecular analyses after 7-10 days of persistent hyperglycemia (blood glucose
level of above 300mg/dl).

Brain stem slice preparation- refer to general methods of Chapter 2.

Electrophysiological recording- refer to general methods of Chapter 2.
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The drugs, and their respective concentrations, used for experiments specific to
this chapter were: Tetrodotoxin (TTX; 1-2 µM; Alomone Labs) DL-2-Amino-5phosphonopentanoic acid (AP-5; 100 µM, Sigma), N-methyl-D-aspartic acid
(NMDA; 15 µM; Sigma), picrotoxin (PTX; 100 µM, Sigma), d-tubocurarine
chloride (DTC 10-20 μM; Sigma), Strychnine (1-2 µM; Tocris), 6-Cyano-7nitroquinoxaline-2,3-dione (CNQX; 10 µM, Sigma). To measure current
responses at membrane potentials of at membrane potential of -110 to +30 mV,
voltage steps were applied at 10 mV increments. Steps were of 1 second
duration to reach maximal current responses for each voltage measured.
Incremental current step were made at inter-step-intervals of 400 ms. Current
measurement were averages of four runs and were measured at each potential
at the end of the voltage step. A current-voltage response graphs was
extrapolated from these measurements and compared between control and T1diabetic mice.

RNA isolation
Two to three brainstem slices (300-600 μm) were isolated as described for
electrophysiological recordings. The DVC was carefully excised and tissue
sample and suspended in 400-500 µL of TRIzol® and gently shaken periodically
for 5-25 min. 100-250 µl of chloroform was added the tubes vortexed for 15sec
and maintained at 4ºC for 20 min or incubate them 2-3 min at RT and
subsequently centrifuged at 12,000 rpm for 10-15 min at 4ºC. RNA supernatant
was transferred into fresh 1.5 ml centrifuge tubes and suspended in 500 µL of
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ice-cold propanol. Resuspended samples were incubated at room temperature
for 10 minutes and subsequently centrifuged at 12,000 rpm for 10 min at 4ºC.
Propanol was decanted and RNA was washed by resuspension in 500 µL 75%
EtOH followed by centrifugation at 7500-12,000 rpm for 10 min at 4ºC. This
wash step was repeated, the EtOH decanted. RNA samples were air-dried for
10-20 min. RNA samples were resuspended in 8-10 µL RNAse-free water and
stored at -80 ºC or immediately reverse transcribed into cDNA. When obtaining
single-cell mRNA the cytosol of the cell was aspirated into the recording pipette
using. Negative pressure was removed and the recording pipette carefully
removed and its contents were then expelled into a sterile centrifuge tube. RNA
was stored at -80 ºC or immediately reverse transcribed into cDNA

TaqMan PCR
RNA samples were reverse transcribed in Reverse-Transcription Master
Mix (1 µl random nonamers (50 uM) (Sigma), 5 µl MMLV RT buffer (5x) (Fisher),
5 µl dNTPs (10 mM) (ThermoScientific), 2 µl DEPC-treated H2O (Fisher), 1 µl
Reverse Transcriptase (Fisher), and 1 µl RNAse Inhibitor (Fisher). For single-cell
RT-PCR experiments, the cytosol was aspirated following electrophysiological
recordings and suspended in RNA RNA Reverse-Transcription Master Mix
without enzymes and stored at -80 ºC until further use. Groups of cells were
reverse transcribed after the addition of 1 µl Reverse Transcriptase (Fisher), and
1 µl RNAse Inhibitor (Fisher) in a thermocycler (Eppendorf Mastercycler) at 42ºC
for 90 min followed by 5 min at 95ºC. For phenotype identification, positive
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controls (tissue samples) and single cells were probed for the presence of betaactin and VGLUT2. Primers and probes for beta-actin were: fwd,
CAGCAGGTACAGCATCACGG; rev, GCCATGTACGTAGCCATCC; probe,
CTGGTCGTACCACAGGCATTGTG; and for VGLUT2: fwd,
CCCGTCTACGCGATAATTGTT; rev, GTCATGACAAGGTGAGGGACT; Probe,
ACTGCTCATCAGCCAGCTT. Mastermix containing 3 µl (beta-actin) or 2 µl
(VGLUT2) MgCl2 (25 mM), 2.4 µl PCR buffer (10x), 1 µl dNTPs (10 mM), 1 µl
primers/probe (10 uM), 0.5 DNA polymerase and 14 µl was prepared and 3 µl of
single cell or positive control RNA or RNAse free sterile H2O (non-template
control) loaded into optical tubes or a 96-well plate (Bio Rad). Samples were
centrifuged for 2 min at 1000 RPM and placed in an ABI-Thermocylcer for PCR
analysis. Samples were held at 95 ºC 2 min and cycled 50 times at 95 ºC for 30
s, 60 ºC for 15 s and at 72º C 15 s.

NanoString® gene expression
A custom designed codeset was designed by and purchased from
NanoString technologies (for complete list see Appendix 4). This codeset
included the seven known NMDA receptor subunits (NR1, NR2A-D and NR3A-B)
as well as four housekeeping genes (beta-actin, GAPDH, Hprt1, Ubc). The
isolated RNA quality assessment and concentration determination was made at
the University of Kentucky using the Agilent's Bioanalyzer 2100. The average
RNA integrity number (RIN) for samples used in this study were 9.4 ± 0.07
(Range: 8.9-9.7). 100 ng of total RNA was used from each sample. Hybridization
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reaction using the custom designed codeset, and nCounter® master mix, was
performed according to protocol by the microarray facility at the University of
Kentucky using the nCounter® from NanaString® Technology. The NanoSting
probe identifiers for genes analyzed throughout this dissertation were: For NR1:
NM_008169.2:492, for NR2A: NM_008170.2:4080, for NR2B:
NM_008171.3:6340, for NR2C: NM_010350.2:2720, for NR2D:
NM_008172.2:1201, for NR3A: NM_001033351.1:1332, for NR3B:
NM_130455.2:2030, for beta-actin: NM_007393.3:1138, for GAPDH:
NM_001001303.1:890, for Hprt1: NM_013556.2:30, for Ubc: NM_019639.4:21.
For a more complete list of probes included in these analyses refer to Appendix
2. Normalization was performed using the nSolver™ software from NanoString®
Technology. The nSolver® software normalizes to negative and positive controls
to eliminate background noise and variability unrelated to samples. To calculate
the normalization factor of these controls the geometric mean (geometric mean=
𝑛

√𝑥1 𝑥 2 … 𝑥 𝑛 ) of each sample is obtained. Subsequently, to account for variability

between samples the geometic mean of samples is taken. This average is
divided by individual sample specific geometric means to calculate a

normalization factor, which is multiplied by sample specific counts. Normalization
of endogenous control genes, is subsequently conducted, on counts normalized
to positive and negative controls using the same workflow of normalization used
for positive and negative controls.

Western Blots
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Brainstem slices (300-600 μm) were isolated as described for
electrophysiological recordings. Slices were immediately transferred to 40-60 µl
of lysis buffer consisting of 0.15M NaCl, 5mM EDTA (pH 8), 1% Triton X-100,
10mM Tris-Hcl (pH 7.4), 10ul/ml of 100mM PMSF (174.2 mg/10ml in methanol),
and 100ul/ml of 0.5M NaF (pH 10). Each sample was sonicated and centrifuged
immediately at 12,000 RPM for 3 min. Supernatant was aspirated, aliquoted, and
stored at -80 ºC until further use. Protein concentration was measured using a
Bradford Protein Assay. For Western blots, 20 µg of protein was loaded per lane.
The appropriate volume of sample together with equal amounts of loading buffer
were boiled in water for 2 min. Samples and ladder were loaded into precast PDF
gels in and subsequently the gel was electrophoresed at 50 mA for 45–80 min.
Proteins were then transferred at 200 mA for 2 hrs onto polyvinylidene difluoride
membranes for Western blot analysis. Membranes were blocked in 1:1 Odyssey
blocking buffer/PBS/0.1% Tween 20 for 1 hr at room tremparature. Due to well
separated molecular weights of the NR1 (band at 105-120 kD) and β-actin (band
at 40-45 kD) protein membranes could be cut in half to be incubated over-night at
4°C, with a rabbit monoclonal anti-NMDAR1 (1:1000; Abcam) and a rabbit
monoclonal anti-β-actin (1:10000; Abcam) antibody in Odyssey blocking
buffer/PBS/0.1% Tween 20. Membranes were washed with 4 times 5 min with
PBS on a shaker. After the final wash membranes were scanned on a
densitometer (Odyssey model 9120, Li-COR Biosciences) to quantify band
density. Background density was subtracted from the NMDAR1 and β-actin band
density and normalized to β-actin, which was used as a loading control.
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Data analysis- see general methods of chapter 2.
Results
Glutamate release in the DMV of T1-diabetic mice is increased
Whole-cell patch-clamp recordings were made from DMV neurons from
control and T1-diabetic mice, voltage-clamped at -80 mV in the presence of the
GABA-A receptor blocker picrotoxin to isolate AMPA-mediated synaptic currents.
To record mEPSCs tetrodotoxin (1-2 µM) was added to the ACSF. The
frequency of both sEPSCs (control: 11.80 ± 1.46 Hz, n=16; T1-diabetic: 26.05 ±
5.44 Hz, n=20) and mEPSCs (control: 12.98 ± 1.43 Hz, n=55; T1-diabetic: 24.34
± 4.53 Hz, n=20 ) was greater in in T1-diabetic mice when compared to control
animals (p<0.05; Figure 4.2C). No change in amplitude was observed for
sEPSCs (Figure 4.2D). Consistent with previous reports, glutamate release was
enhanced in the DMV of T1-diabetic mice (Zsombok et al., 2011; Zsombok and
Smith, 2009).
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Figure 4.2 Comparison of sEPSC and mEPSC in control and T1-Diabetic mice in
the presence of picrotoxin confirmed an increase in the frequency without a
change in amplitude. A. Representative trace of sEPSCs in a control and T1
Diabetic mouse. B. Representative of mEPSCs in a control and T1 Diabetic
mouse. C. Group frequencies and amplitudes in control and T1 Diabetic mice.
Underlined sections indicate regions expanded below. A significant increase in
sEPSC and mEPSC was observed in T1-diabetic mice using a homoscedastic
Student’s t-test and * indicates significance of p<0.05.
NMDA receptor-mediated modulation of glutamate release in the DMV is
increased in diabetic mice.
Tonically active NMDA receptors (i.e., activated by ambient glutamate in the
slice) located on glutamatergic terminals were described previously in the DMV
(Bach and Smith, 2012). The hypothesis that sensitivity of these receptors was
enhanced in T1-diabetic mice, resulting in increased glutamate release was
tested. The response to the NMDA receptor antagonist AP-5 was compared
between normoglycemic and hyperglycemic T1-diabetic mice to reveal tonically
activated NMDA receptors. DMV neurons were voltage clamped at -80 mV, to
diminish the effect of postsynaptic NMDA receptor activation and concentrate
resultant effects on presynaptically mediated mechanisms. Application of AP-5
resulted in a significant decrease in the frequency of sEPSCs in both
normoglycemic mice, decreasing sEPSC frequency from a baseline of 13.42 ±
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2.81 Hz to 10.08 ± 1.89 Hz during application of AP-5 (n=5; p<0.05). Similarly,
application of AP-5 also diminished sEPSC frequency in hyperglycemic, T1diabetic mice from a baseline of 16.85 ± 4.68 Hz to 10.42 ± 3.46 Hz during
application of AP-5 (n=6; p<0.05; Figure 4.3C). No change in amplitude was
observed in control (baseline 18.822 ± 1.93 pA and 18.83 ± 1.59 pA during
application of AP-5) or T1-Diabetic mice (baseline 20.46 ± 2.02 pA and 18.47 ±
2.11 pA during the application of AP-5). There was a significantly greater percent
decrease in the frequency of T1-diabetic than normoglyemic mice (23.78 ± 1.74
% change in controls (n=5), 40.65 ± 1.98 % change T1-diabetic mice (n=6);
p<0.05; Figure 3D). This result suggested that NMDA receptors exert a greater
tonic enhancement of glutamate release in the DMV of T1-diabetic than in
normoglycemic mice.
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Figure 4.3 AP-5 application on sEPSCs revealed a greater relative effect on the
frequency in T1-Diabetic than control mice A. Representative trace showing
sEPSCs in a slice from a control mouse under baseline conditions and following
the application of AP-5. B. Representative trace from an T1 Diabetic mouse
under baseline conditions and following the application of AP-5. C. Average
group sEPSC frequency in control and STZ-treated mice before, during and after
the application of AP-5. D. Average group percent decrease in sEPSC frequency
following application of AP-5 in control and T1 Diabetic mice. Line above
indicates section expanded below. * and # indicate significance from intragroup
72

responses to AP-5 application using a paired two-tailed Student’s t-test of
p<0.05. Intergroup differences were analyzed using a two-way Anova.
Preterminal NMDA receptors tonically modulate glutamate release in both
normoglyemic and T1-diabetic mice
Since sEPSCs reflect both action potential-dependent and -independent
glutamate release, NMDA receptor-mediated differences in sEPSC frequency
between control and T1-diabetic mice could result from changes in receptors
located on terminals contacting DMV neurons and/or soma-dendritic receptors on
presynaptic neurons. Preterminal NMDA receptors were previously identified in
normoglycemic mice, which function to enhance glutamate release tonically in
the DMV (Bach and Smith, 2012). In the presence of PTX and TTX, application
of AP-5 (100 µM) decreased mEPSC frequency in DMV neurons from a baseline
of 12.84 ± 3.58 Hz to 8.97 ± 2.48 Hz in AP-5 (n=10; p<0.05). No change in
amplitude (19.75 ± 1.83 pA versus 19.23 ± 1.51 pA) or decay time (1.74 ± 0.13
ms versus 1.68 ± 0.15 ms in AP-5; p=0.44) was observed. Application of AP-5 in
of T1-diabetic mice also resulted in a significant decrease in the frequency of
mEPSCs in DMV neurons (15.53 ± 4.96 Hz baseline and 9.70 ± 3.28 Hz during
the application of AP-5; n=10; p<0.05; Figure 4.4 C). Neither mEPSC amplitude
(20.04 ± 1.74 pA versus 19.28 ± 1.43 pA in AP-5) nor decay time (1.58 ± 0.12 ms
versus 1.62 ± 0.09 ms in AP-5) was altered (Figure 4.4 C). The relative effect on
mEPSC frequency of AP-5 in control (31.12 ± 5.67% decrease; n=9) versus T1diabetic animals (31.90 ± 6.04% decrease; n=10) was not different (p>0.05;
Figure 4.4D). This result suggests that preterminal NMDA receptors tonically
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modulate glutamate release in the DMV of T1-Diabetic mice to a similar degree
as in normoglycemic controls. Since baseline mEPSC frequency was elevated in
the DMV of T1-diabetic mice, effects of AP-5 as a function of baseline mEPSC
frequency were determined. No correlation was detected, however, between
baseline mEPSC frequency and relative AP-5-mediated response in control (R2=
0.02) or T1-diabetic (R2= 0.09) mice. Although AP-5 was effective in reducing
mEPSC frequency in both groups, the relative effect of blocking preNMDA
receptors on glutamate release was similar for normoglycemic and T1-diabetic
mice. These results, therefore, were not consistent with altered function of
preNMDA receptors in mediating the observed differences in NMDA receptormediated modulation of glutamate release in the DMV of T1-diabetic mice.
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Figure 4.4 The tonic inhibition of mEPSC frequency in response to AP-5 was
similar T1-diabetic and control mice. A. Representative traces showing mEPSCs
in a slice from a control mouse before, during and after the application of AP-5.
B. Representative traces from an T1 Diabetic mouse before during and after the
application of AP-5. C. Average group mEPSC frequency, amplitude and decay
times in control and T1 Diabetic mice before, during and after the application of
AP-5. D. Average group percent decrease in mEPSC frequency following
application of AP-5 in control and T1 Diabetic Mice. E. Correlation of baseline
frequency and percent change of frequency in response to AP-5. Line above
traces indicate section expanded below. * and # indicate significance from
intragroup responses to AP-5 application using a paired two-tailed Student’s ttest of p<0.05. Intergroup differences were analyzed using a two-way Anova.
NMDA receptor-mediated whole-cell currents in NTS neurons were
enhanced in T1-diabetic mice
To determine if sensitivity of afferent neurons to NMDA was increased in
T1-diabetic mice, whole-cell currents were recorded in NTS neurons in response
to applied NMDA. To isolate NMDA receptor-mediated responses, all recordings
were made with a Cs+-gluconate-based internal solution to block K+ currents and
in the presence of TTX (1-2 µM), PTX (100 µM), strychnine (1-2 µM), DTC (20
µM), and CNQX (10 µM ) to block action potentials, GABA-A, nicotinic, and
AMPA receptors, respectively. When applying 300 µM NMDA to NTS neurons
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recorded while voltage-clamped at a holding potential of -30 mV, T1-diabetic
mice exhibited significantly greater whole-cell current responses were observed
in neurons from T1-diabetic mice (259 ± 31 pA; n=22) than controls (175 ± 25 pA;
n=21; p<0.05). To account for cell size, current densities were calculated by
normalizing each cell to cell capacitance, which did not differ between animal
groups (14.2 ± 0.84 pF controls, 13.2 ± 1.06 pF T1-diabetic; p=0.45). When
normalized to cell capacitance, NTS neurons from T1-diabetic mice had
significantly greater NMDA-evoked current density (21.4 ± 3.2 pA/pF) than
controls (12.5 ± 1.2 pA/pF; p<0.01; Figure 4.5B). Using TaqMan based single cell
RT-PCR, a subset of neurons from both groups was identified as glutamatergic
(i.e., expressed VGLUT2; Figure 4.5D). When NMDA-evoked whole-cell currents
and current densities were compared in this glutamatergic subpopulation of NTS
cells, both whole-cell current (75.4 ± 24.3 pA controls; 258 ± 18.6 pA T1-diabetic;
p<0.01) and current density (6.7 ± 2.2 pF controls, 18.1± 2.4 pF T1-diabetic;
p<0.01), were significantly greater in T1-diabetic (n=5) than control (n=5) mice.
This result suggests that NMDA receptor activation was enhanced in
glutamatergic NTS neurons from diabetic mice and this enhancement could
account for the greater relative increase in glutamate release in the DMV of
diabetic mice in response to AP-5 application.
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Figure 4.5 NMDA mediated whole cell current (WCC) responses and current
densities in NTS neurons of control and T1-diabetic mice. A. Representative
traces of NMDA (300 µM) mediated WCC responses in control and T1-diabetic
mice. B. Average NMDA mediated WCC in control and T1-diabetic of the total
(n=21 controls, n=22 T1-diabetics) and the VGLUT2+ (n=5 controls, n=5 T1Diabetics) NTS neurons population (asterisk indicates significant difference from
control, p<0.05). C. Average NMDA mediated current densities in control and
T1-diabetic of the total (n=21 controls, n=22 T1-diabetics) and the VGLUT2+
(n=5 controls, n=5 T1-diabetics) NTS neuron population (asterisk indicates
significant difference from control, p<0.05). D. Example of a VGLUT2+ neuron.
Voltage-dependence of soma-dendritic NMDA Receptors in NTS neurons
Responses to NMDA were determined in neurons voltage-clamped at -30
mV, a potential presumed to reveal maximal NMDA receptor-mediated
responses (Mayer et al paper; Smith et al., 1998). To determine if the voltagedependence of the NMDA induced responses differed between NTS neurons of
control and diabetic mice, a voltage step protocol was applied in a subset of
neurons and currents evoked by NMDA application (300 µM) were examined at
voltages between -80 and 30 mV. NMDAR responses were recorded in the
presence of PTX, TTX, strychnine, DTC and CNQX. The current-voltage
relationship was determined during the maximal NMDA receptor- mediated
response. When comparing the NMDA receptor-mediated current, calculated as
the current density at each voltage in NMDA minus the current density at each
respective baseline voltage, there was a significant increase in the current
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density in NTS neurons from T1-diabetic (n=21) versus control (n=12) mice at all
voltages between -40 to 0 mV (p<0.05; Figure 4.6A).
Maximal activation of the NMDA receptor is thought to occur near -30 mV
due to Mg2+ dependent block (Mayer et al., 1984), and our experimental results
are therefore in agreement with this response being NMDA-mediated. There was
no significant difference between the baseline holding current responses of the
two animal groups (Figure 4.6B). The observed responses exhibited a nonlinear
current-voltage relationship consistent with a voltage-sensitive response. Most
importantly, at the theoretical maximum response to NMDA (-30 mV) there was a
greater NMDA-mediated current density in T1-diabetic than control mice (-8.8 ±
1.47 pA/pF control, n=12; -17.1 ± 1.99 pA/pF T1-diabetic, n=21); p<0.05) (Figure
4.6A). The NMDA response was reversible (n=8 controls; n=11 T1-diabetic;
Figure 4.6.C and D) and the NMDA receptor specificity was confirmed using AP5 (which blocked the response) in a subset of cells (n=3; Figure 4.6.E).
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Figure 4.6 Current-voltage responses in control and T1-Diabetic mice. A. NMDA
(300 µM) mediated current-voltage responses in control (n=12) and T1-Diabetic
(n=21) mice. B. Baseline current-voltage responses in control and T1-Diabetic
mice (asterisk indicates significant difference from control, p<0.05). C. Currentvoltage responses of reversible NMDA mediated responses in control (n=8) mice.
D. Current-voltage responses of reversible NMDA-mediated responses in T1Diabetic (n=11) mice. E. Current-voltage responses of AP-5 dependent reversible
NMDA-mediated WCC (n=3). F. Representative examples of current-step
responses before and during the application of NMDA in control and T1-Diabetic
mice and stimulus waveform used in these studies. * indicates p<0.5 using a twosample equal variance two-tailed Student’s t-test.
Western Blot analysis of NR1 Subunits
The NR1 subunit is an obligatory NMDAR subunit (Traynelis et al., 2010).
An NR1 antibody raised against this subunit was used to examine protein levels
as a measure of possible differences in the number of NMDA receptors between
control (n=6) and T1-Diabetic (n=6) mice (Fig. 4.7). A discrete band at 105-120
kD was observed that was consistent with the NR1 protein. Band density was
normalized to that of β-actin. No statistically significant difference between the
relative expression of the NR1 subunit between control and T1-diabetic mice was
observed (100 ± 22 % controls and 126 ± 13 % T1 diabetic mice; p=47).
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Figure 4.7 Protein expression of the NR1 subunit in control and T1-diabetic
mice. A. Representative examples of NR1 subunit and ß-actin protein expression
in the DVC of control (n=6) and T1-diabetic (n=6) mice. B. Average NR1 protein
expression in the DVC of control and T1-diabetic mice. Statistical significance
was analyzed using a Wilcoxon signed-rank test.
NMDA receptor subunit RNA abundance
The RNA expression of the seven NMDA receptor subunits was
quantitatively using the nCounter NanoString technology. All genes were
normalized to positive and negative internal controls. Genes of interest were
subsequently normalized to the four control genes, beta-actin, GAPDH and
Hprt1. No differences in RNA abundance was detected in any of the seven
NMDA receptor subunits were observed between control and T1-diabetic mice
(Fig 4.8). The average RNA abundance for each NMDA receptor subunit is
expressed in Table 4.1. below.
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Table 4.1. NMDA receptor subunit mRNA abundance

Gene

Control

T1-diabetic

NR1

1562 ± 60

1585 ± 96

NR2A

561 ± 61

456 ± 71

NR2B

704 ± 22

714 ± 49

NR2C

132 ± 8

132 ± 6

NR2D

323 ± 19

329 ± 31

NR3A

1451 ± 44

1567 ± 33

NR3B

39 ± 7

45 ± 6
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Figure 4.8 NMDA receptor subunit RNA abundance in normal and T1-diabetic
mice. Intergroup differences in gene expression were analyzed using a two-tailed
two-sample equal variance Student’s t-test.

Discussion
In this study, mechanisms underlying increased mEPSC and sEPSC
frequency of DMV neurons inT1-diabetic mice were investigated This study
confirmed the increase in mEPSC and sEPSC frequency in T1-diabetic mice first
observed by Zsombok et al.(Zsombok et al., 2011). The frequencies reported
here were observed in the presence of a GABA-A antagonist to mitigate against
possible network effects that might influence glutamate release in the DMV
(Derbenev et al., 2006; Glatzer and Smith, 2005; Smith et al., 1998; Williams et
al., 2007). Additionally, unlike previously, animals were maintained
hyperglycemic for at least 7 and up to ten days before being used for
electrophysiological and or molecular experiments and recordings were
performed with 2 mM CaCl rather than 1.3 mM. All of these factors could
contribute to the slightly larger enhancement of glutamate release versus that
observed previously, but do not detract from the primary conclusion that
excitatory input to DMV neurons is increased in T1-diabetic mice. The absence of
an amplitude change suggests that excitatory neurotransmission is altered
presynaptically, either at the terminal or on the presynaptic neuron.
NMDA receptors have been studied extensively for their involvement in
enhancing excitatory neurotransmission under pathological conditions (Yang et
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al., 2006). Antagonism of NMDA receptors in acute brainstem slices resulted in a
greater relative decrease in sEPSC frequency, without an amplitude change, in
T1-diabetic mice. This result established the involvement of NMDA receptors in
circuitry changes of the DVC resultant to T1-diabetes. The AP-5-induced
decrease in the frequency suggested a decrease in the probability of glutamate
release at the presynaptic terminal and/or the soma-dendritic membranes of
intact presynaptic neurons (Figure 4.1). An increase in sEPSC and mEPSC
frequency (observed in this and previous studies by Zsombok et. al) in the
absence of a change in amplitude of T1-diabetic mice posed NMDA as a
probable mechanistic player in mediating the enhanced excitatory drive onto
DMV neurons.
Activation of NMDA receptors located on presynaptic glutamate terminals
was previously identified as a means of modulating glutamate release in the
DMV (Bach and Smith, 2012). To determine if changes in NMDA receptors
located on glutamatergic synaptic terminals contacting DMV neurons accounted
for the relative differences in NMDA-dependent modulation of glutamate release,
action-potential independent responses were isolated through the use of TTX.
PreNMDA receptors were active tonically in both control and diabetic mice.
When comparing the two animal groups, however, the relative contributions of
NMDA receptors located on presynaptic terminals to tonic facilitation were
similar. This result argues against preNMDA receptors contributing directly to the
enhanced mEPSC frequency observed in T1-Diabetic mice.
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To explain the greater relative NMDA effect on sEPSC frequency in T1diabetic mice, soma-dendritic NMDA receptor responses of putative presynaptic
neurons in the NTS were compared between groups. Functional glutamatergic
synaptic connections between NTS and DMV neurons are maintained in the
brainstem slice preparation used in this study (Davis et al., 2004; Davis et al.,
2003; Derbenev et al., 2004). NMDA-mediated whole-cell current amplitude and
current density was increased in NTS neurons of T1-diabetic mice relative to
controls. The differences between groups were consisted in glutamateric (i.e.,
VGLUT2-expressing) NTS neurons, indicating that increased NMDA enhanced
excitatory drive of glutamatergic NTS neurons represents a hallmark feature in
T1-diabetic mice. Whereas NMDA sensitivity differences between groups was
detected across the global NTS neuronal population, the range of responses
exhibited considerable overlap between groups. In contrast, the response
amplitude in identified VGLUT2+ neurons in T1-diabetic mice was consistently
greater than in controls. The NTS includes a number of prominent phenotypes in
addition to glutamate, including GABAergic, noradrenergic, and a variety of
peptides. With respect to fast synaptic transmission to the DMV, glutamate and
GABA predominate (McDougall and Andresen, 2012; McDougall and Andresen,
2013). The frequency of GABAergic IPSCs, however, was not altered in T1diabetic mice. This suggests that tonic activity of GABAergic neurons does not
contribute substantially to modulation of DMV function in T1-diabetic mice and
also implies minimal contribution of altered tonic NMDA activation in NTS GABA
cells to DMV neuron function in these mice. Although more direct assessment of
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NMDA activity in GABA cells is required to be definitive, the consistently greater
effect of NMDA in identified glutamate neurons from T1-diabetic mice may reflect
phenotype-selective alteration of NMDA-dependent regulation of glutamate
neurons in the NTS that project the DMV.
Although specificity of the increased NMDA sensitivity to glutamate
neurons could not be determined conclusively, the relative sensitivity of this
population is consistent with enhanced NMDA receptor-mediated activation of
glutamatergic NTS neurons and is consistent with the enhanced glutamate
release seen in T1-diabetic mice. The increased NDMA sensitivity in
glutamatergic NMDA neurons is consistent with the increase increased sEPSC
frequency in downstream DMV neurons.
NMDA receptor modulation of whole-cell current responses in NTS
neurons could be due to changes in the number of receptors present,
reorganization of receptor subunits, and/or receptor trafficking (Collingridge et al.,
2004; Traynelis et al., 2010). The total number of receptors should be reflected
by the expression of the NR1 subunit, since incorporation of this subunit is
obligatory for functional NMDA receptor assembly (Paoletti et al., 2013). When
protein expression of the NR1 subunit was compared between control and T1Diabetic mice, no statistically significant differences were observed. The lack of
significance may reflect, at least in part, the lack of phenotype specificity of the
method used to detect protein differences in a heterogeneous cell population.
This sensitivity in cell population may also account for the failure to observe
significant changes in gene expression of the NMDA receptor subunits.

88

Additionally, expression changes between specific cell populations may be
altered differentially, with some cell populations showing increased expression
and others showing a decrease in expression. All these factors may account for
the failure to identify protein expression and mRNA expression changes in
NMDA receptor subunits and argues for the need to more specifically target
distinct populations of cells, possibly through the use of transgenic animals that
allow fluorescent genotypic identification. Finally, receptor trafficking may
account for changes in NMDA-mediated electrophysiological measures and
could be independent of expression changes (see Chapter 6 for more extensive
discussion).
Neurons in the vagal complex respond to altered glucose concentrations
and also influence blood glucose content. Subsets of dorsal vagal complex
neurons and synaptic terminals are glucose-sensitive (Balfour et al., 2006;
Balfour and Trapp, 2007; Ferreira et al., 2001; Wan and Browning, 2008),
consistent with longstanding evidence that glucose-sensing neurons in this
region regulate both feeding and blood glucose concentrations (Ritter et al.,
1981; Ritter et al., 2000). Acutely, injection of glucose into the vagal complex
inhibits gastric motility and increases intragastric pressure, most likely by
inhibiting activity of DMV neurons (Ferreira et al., 2001). Vagally-mediated
visceral function can also be compromised in chronically hyperglycemic animal
models or human patients with either type 1 or type 2 diabetes (Ahren et al.,
1996; Pocai et al., 2005b; Saltzman and McCallum, 1983; Undeland et al., 1998).
Decreased parasympathetic visceral tone resulting from vagal atonia leads to a
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number of outcomes detrimental to maintenance of metabolic homeostasis,
including elevated hepatic gluconeogenesis and diabetic gastroparesis (diabetic
gastropathy). A greater sensitivity of NMDA receptors in glutamatergic
projections to the DMV could serve as a mechanism to counter the inhibitory
effects of hyperglycemia on vagal output by increasing excitatory synaptic input
to preganglionic parasympathetic motor neurons. In addition to insulin-dependent
receptor trafficking (Zsombok et al., 2011), synaptic glutamate release in the
DMV is persistently increased the STZ-treated mouse. DMV motor neurons are
‘pacemakers’ that fire action potentials tonically (Browning and Travagli, 1999).
Their activity is tightly regulated by synaptic inputs, largely arising from GABA
and glutamate neurons of the adjacent NTS (Davis et al., 2003; Glatzer et al.,
2007; Travagli et al., 1991a; Williams et al., 2007). Normally, GABAergic input
from the NTS to DMV neurons dominates the tonic regulation of vagal output,
whereas glutamatergic regulation is thought to be more phasically active
(Browning and Travagli, 2011) A sustained increase in glutamatergic, excitatory
synaptic drive to DMV motor neurons in diabetic mice would be expected to
enhance the tonic influence of glutamate in the DMV and increase vagal output,
leading to diminished hepatic gluconeogenesis and/or enhanced output to the
exocrine pancreas, as well as attenuation of diabetic gastroparesis (Ahren et al.,
1996; Saltzman and McCallum, 1983). Significant, sustained modulation of
excitatory synaptic function in the DMV of T1-diabetic mice thus involves a
fundamental change in the balance of synaptic input to vagal motor neurons. In
this sense, the altered synaptic balance may be an attempt by the system to
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homeostatically compensate for putatively excessive inhibition of vagal activity in
chronic hyperglycemia by increasing DMV neuron excitability. NMDA sensitivity
in glutamatergic NTS neurons is increased in T1-diabetic mice and at least a
portion of the chronically-enhanced glutamate release seen in these animals may
be due to tonically enhanced NMDA-dependent modulation of NTS neurons.
Chronic dysregulation of visceral autonomic control may contribute to
development of insulin resistance and type 2 diabetes (Carnethon et al., 2003).
NMDA receptor plasticity might represent a compensatory response to chronic
hyperglycemia associated with diabetes and may therefore provide clues to reestablishing autonomic control in diabetic patients.

91

Chapter 5: Preterminal Glycine Receptor modulation of glutamate release
in the dorsal vagal complex

Introduction
Glycine receptors (GlyRs) are pentameric, ionotropic chloride receptors
activated by glycine. Although they are found throughout the central nervous
system, their expression level is particularly high in the spinal cord and
brainstem. Structurally they are members of the cys-loop receptor family, all of
which are arranged in a symmetrical ring structure around a central ionconducting pore. Like other ligand-gated ion channels, GlyRs consist of an Nterminal, a transmembrane, an extracellular domain and an intracellular loop that
connects the four transmembrane segments (Lynch, 2009). Glycine binds in the
extracellular domain and alternative splicing in this domain can alter glycine
efficacy (Dutertre et al., 2012).
GlyRs can consist of heteromeric arrangements of α- and β-subunits or
homomeric arrangements of α subunit isoforms. There are four α-subunit
isoforms, namely α1- α4 and a single β-subunit. Functional changes resulting
from subunit arrangements, are poorly understood due to the lack of
pharmacological agents available to target specific receptor isoforms.
Homomeric β-subunits do not appear to assemble into functional receptor
channels (Lynch, 2009). Embryonic neurons express primarily homomeric αsubunit GlyRs, but these are gradually replaced to make α- and β-subunit
heteromeric GlyR predominant by the third postnatal week in rats (Lynch, 2009).
Co-assembly of α- and β-subunits not only results in a reduced picrotoxin
92

sensitivity, but also reduces single channel chloride conductance (Beato et al.,
2004; Burzomato et al., 2004; Lynch, 2009; Pribilla et al., 1992).
GlyRs have long been studied for their contribution to the postsynaptic
membrane potential. More recently, however, their effects on the probability of
neurotransmitter release at the presynaptic terminal has been investigated
(Turecek and Trussell, 2001). In the visual neocortex, the auditory brainstem,
spinal cord, and a few other regions of the brain, preterminal glycine receptors
(preGlyRs) have been identified to tonically increase the release of glutamate as
well as GABA (Ye et al., 2004). The enhancement of neurotransmitter release by
glycine receptor activation was shown to be dependent on Ca2+ entry through
voltage-gated Ca2+ channels (VGCCs) (Jeong et al., 2003; Kunz et al., 2012;
Turecek and Trussell, 2001).
Chloride conductance through GlyRs can be either hyperpolarizing and
depolarizing, depending on the membrane potential relative to the Cl- equilibrium.
Two pumps, namely the Na+- K+-Cl- co-transporter 1 (NKCC1) and K+-Cl- cotransporter 2 (KCC2), are pivotal players in establishing the Cl- equilibrium
potential which dictates the effect Cl- influx imparts on the cell membrane
potential. While NKCC1 transports chloride into the cell to increase the
Cl- equilibrium potential (i.e., makes ECl- more depolarized), KCC2 transports
Cl- out of the cell and consequently lowers the Cl- equilibrium potential (Payne et
al., 2003). Throughout development the two transporters show opposing
expression patterns, with NKCC1 expression being high in early development
when KCC2 expression is low. As NKCC1 moves towards its low adult
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expression levels, KCC2 expression increases. As a result, the increased KCC2
to NKCC1 ratio causes Cl- flux through GlyRs to become progressively more
hyperpolarizing (Song et al., 2006; Turecek and Trussell, 2001; Ye et al., 2004)
Glycine is removed from the synaptic cleft through Na+/K+-ATPase cotransport coupling of glycine transporters (GlyTs) (Mayor et al., 1981). Two
GlyTs, namely GlyT1 and GlyT2, have been identified. These two transporters
differ in their co-transport stoichiometry and more controversially in their
subcellular localization (Aragon et al., 1987; Cubelos et al., 2005; Poyatos et al.,
1997; Zafra et al., 1995). GlyT1 co-transportation has a stoichiometry of 2
Na+:K+:glycine, while GlyT2 maintains a 3 Na+:K+:glycine stoichiometry (Aragon
et al., 1987; Betz et al., 2006). Differences in GlyTs cellular localization is thought
to play an important role in dictating the effect these transporters have on glycine
availability within the synaptic cleft (Berger et al., 1998; Bergeron et al., 1998).
GlyT1 is thought to be localized primarily in astrocytes and in a small
subpopulation of neurons, while GlyT2 is thought to colocalize specifically with
glycinergic neurons (Poyatos et al., 1997; Zafra et al., 1997b). This localization
specificity is believed to result in opposing functions of the two transporters, with
GlyT1 clearing glycine form the synaptic cleft and GlyT2 leading to more efficient
glycine recycling (Zafra et al., 1997a). Recent studies in various areas of the
CNS, however, have challenged the cellular localization specificity of GlyTs
(Cubelos et al., 2005; Raiteri et al., 2008). In the spinal cord, experimental
evidence suggests co-localization of the two transporters on gliosomes and
synaptosomes, and GlyT1 expression has been found on both GABAergic and
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glutamatergic terminals, as well as in interneurons (Cubelos et al., 2005; Menger
et al., 1998; Raiteri et al., 2008).
GlyR and GlyTs have been implicated for their role in pathological
conditions (Eulenburg et al., 2005; Harvey et al., 2008). The availability of
glycine is normally regulated partially by GlyTs and abnormal functions of GlyTs
results in a variety of pathologies. GlyT2, for example, has been well established
for its role in hyperekplexia, a neurological disorder characterized by pronounced
startle responses and hypertonia. Mutations of GlyR, particularly the α-subunit,
have been shown to suppress hyperexcitability during seizure activity
(Chattipakorn and McMahon, 2003; Kirchner et al., 2003). Overall these studies
establish a role of glycine receptors and modulators of glycine availability in
disorders of neuronal hyperexcitability.
In this study the presence and the physiological function of GlyRs at
preterminal contacts in the DMV was assessed. Their relevance in modulating
neurotransmitter release and altered function during a disease state presented
them as a potential mechanism of underlying changes in the release probability
of glutamate in T1-diabetic mice. Consequently, changes in GlyR function were
also investigated for their possible role in counterbalancing hyperexcitability in
DMV neurons of T1-diabetic mice.
Methods
Only methods and materials specific to this Chapter are restated here. To avoid
redundancy refer to Chapter 2 of this dissertation, when indicated.
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Animals
Male and female GIN mice (FVB-Tg (GadGFP)4570Swn/J; The Jackson
Laboratory)4–11 wk of age, were housed under a standard 14-h light/10 –h dark
cycle, with food and water provided without restriction. All animals were treated
and cared for in accordance with National Institutes of Health guidelines and all
procedures were approved by the Institutional Animal Care and Use Committee
of the University of Kentucky.

Animal Injections
Mice were given intra-peritoneal injections of 200mg/kg (either a single dose or in
5 doses of 40 mg/kg each over 5 days) of streptozotocin. Controls were either
injected with saline (0.9% NaCl) or untreated. Systemic glucose levels were
measured prior to injections and monitored daily. Animals were used for
electrophysiological recordings and molecular analyses after 7-10 days of
persistent hyperglycemia (blood glucose level of above 300mg/dl).

Brain stem slice preparation- see general methods in Chapter 2

Electrophysiological recording- see general methods in Chapter 2 for complete
methods.
Drugs used for electrophysiological recording- The drugs, their respective
concentrations, used for specific experiments in this chapter were: DL-2-Amino5-phosphonopentanoic acid (AP-5; 100 µM; Sigma), picrotoxin (PTX; 100 µM;
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Sigma), Tetrodotoxin (TTX; 1-2 µM; Alomone Labs), d-tubocurarine chloride
(DTC; 10-20 μM; Sigma), Strychnine (1-2 µM), Org 24598 (10 µM; Tocris), ALX1393 (0.5 µM; Tocris), Glycine (30 µM,100 µM,300 µM,1000 µM; Fisher), 6Cyano-7-nitroquinoxaline-2,3-dione (CNQX; 10 µM; Sigma), (-)-Bicuculline
methiodide (Bic; 30 µM; Sigma), Bumetanide (10-20 µM; Tocris).

Data analysis- see general methods in Chapter 2
Results
Strychnine antagonism increased mEPSC frequency
Whole-cell recordings were made from DMV neurons at a holding potential of -80
mV in the presence of TTX and picrotoxin to record mEPSCs. Cells were allowed
to equilibrate and were monitored for a minimum of five minutes before baseline
recordings were taken. Strychnine was subsequently bath applied for 10 minutes,
and effects of strychnine on mEPSCs were assessed. Strychnine has been
shown to serve as a potent antagonist of nicotinic α4β2 as well as α7
acetylcholine receptors (Matsubayashi et al., 1998). In the DVC, both α7 and
non- α7 nicotinic acetylcholine receptors facilitate presynaptic glutamate release
(Kalappa et al., 2011). This lack of strychnine specificity necessitated the use of
the nicotinic receptor blocker 10-20 µM d-tubocurarine chloride (DTC) when
examining strychnine-sensitive responses. Initially, DTC was omitted from the
baseline solution. To avoid inadvertent responses on nicotinic acetylcholine
receptors, DTC was included in all subsequent recordings. Strychnine-sensitive
changes in mEPSC frequency did not differ between neurons pre-incubated with
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or without DTC (14.3 ± 0.04 % without DTC, n=6; 14.8 ± 0.04% increase in
mEPSC frequency in response to DTC, n=5; p=0.93). As a result these
populations were combined. In control animals bath application of strychnine
resulted in a small but significant increase in mEPSC frequency (20.79 ± 5.56 Hz
baseline, 23.11 ± 6.25 Hz in response to 1-2 µM strychnine; n=11 p<0.05). The
amplitude of the events also exhibited a small but statistically significant change
(16.42 ± 1.74 pA baseline, 15.05 ± 1.69 pA in response to strychnine; p<0.05).
To additionally test inadvertent effects of NMDA receptor potentiation through
increased glycine availability, the NMDA receptor blocker AP-5 was bath applied.
Inadvertent actions on putative NR3 subunit containing receptors could not be
prevented using this approach (see discussion). In control animals, the
application of strychnine resulted in a small but significant increase in the
frequency of mEPSCs (17.82 ± 4.5 Hz baseline, 21.15 ± 4.4 Hz in response to
strychnine p<0.05; n=5 ; Figure 5.1 C). No change in mEPSC amplitude was
observed (21.17 ±1.66 pA baseline, 21.15 ± 1.74 pA in response to strychnine
p=0.99; Figure 5.1 C). Similarly, In T1-diabetic mice an increase in mEPSC
frequency was observed in response to strychnine (22.90±5.8 Hz baseline,
34.70±5.5 Hz response to strychnine; p<0.05; n=3; Figure 5.1 C). No change in
amplitude was observed (21.17±1.66 pA baseline, 21.15 ± 1.74 pA in response
to strychnine p=0.13). Strychnine therefore increased mEPSC frequency in the
DMV of normal and T1-diabetic mice.
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Figure 5.1 Strychnine antagonism resulted in an increase in mEPSC frequency.
A . Representative recording of mEPSCs in control mice at baseline, in the
presence of PTX, TTX, DTC and AP-5, (upper two traces) and in response to
addition of 1-2μM strychnine (lower two traces) (n=5). B. Representative
recording of mEPSCs in T1-diabetic mice at baseline, in the presence of PTX,
TTX, DTC and AP-5, (upper two traces) and in response to 1-2μM strychnine
(lower two traces) (n=4) . C. Average group frequency and amplitude of mEPSCs
in response to strychnine. Asterisks (*) indicate significant effects of strychnine
(p<0.05); paired two-tailed Student’s t-test). D. Group average percent change
from baseline frequency in response to strychnine (p<0.05; paired, two-tailed
Student’s t-test.
Bumetanide did not alter mEPSC frequency or inhibit the Strychnine
mediated increase in mEPSC frequency
To investigate the involvement of NKCC1 in maintaining the chloride equilibrium
potential at the preterminal membrane, the response of mEPSCs to the NKCC1
inhibitor bumetanide (10 μM, applied for at least 20 min) was assessed.
Bumetanide application did not change the frequency or amplitude of mEPSCs
recorded at -80 mV in the presence of PTX, TTX, DTC and AP-5 (9.41±3.8 Hz
baseline and 10.00±3.6 Hz in bumetanide, p=0.11; 16.94±1.6 pA baseline and
16.12±1.5 pA in bumetanide, p=0.20; n=7; Figure 5.2 A, B and D). When
strychnine was subsequently bath applied, the strychnine mediated increase in
mEPSC frequency persisted (13.53±5.06 Hz at baseline and 15.40±5.2 Hz in
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response to Strychnine, p<0.05; n=6; Figure 5.2 C and D). The amplitude of
these events was unaffected by strychnine (17.41±0.9 pA at baseline and
17.36±0.9 pA in response to strychnine, p=0.88).
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Figure 5.2 NKCC1 inhibition did not alter mEPSC frequency or inhibit the
Strychnine mediated increase in mEPSCs in control mice. A. Representative
recording of mEPSCs at baseline in control mice in the presence of PTX, TTX,
DTC and AP-5 B. Representative recording of mEPSCs during the application of
10μM bumetanide (n=7). C. Representative recording of mEPSCs during the
application of 1-2 μM strychnine (n=6). D. Average group frequency and
amplitude of mEPSCs in response to bumetanide and strychnine. Statistical
significance of drug application was assessed using a paired two-tailed Student’s
t-test. * indicates p<0.05.
Glycine has differential concentration effects on mEPSCs
Glycine at concentrations of 30, 100, 300 and 1000 μM were applied to neurons
recorded at -80 mV in the presence of PTX or Bic, DTC, TTX and AP-5. In
response to 30 μM there was a small but significant increase in the frequency of
mEPSCs (14.53 ± 4.95 Hz baseline, 16.03 ± 4.41 Hz in the presence of 30 μM
glycine p<0.05 n=5; Figure 5.3 A and C). The amplitude of these events was not
changed by glycine (19.02 ± 2.64 pA baseline, 19.74± 3.16 pA in the presence of
30 μM glycine p=0.33). Increasing the concentration of glycine to 100 μM
resulted in a decrease of mEPSC frequency (16.14 ± 2.73 Hz baseline 14.52 ±
2.25 Hz in the presence of 100 μM glycine p<0.05; n=5; Figure 5.3 B and C), with
no effect on mEPSC amplitude (18.56 ± 3.87 pA baseline 18.33 ± 3.44 pA in the
presence of 100 μM glycine p=0.73). While 300 μM (12.54 ± 3.98 Hz baseline
10.65 ± 3.53 Hz in the presence of 300 μM glycine; n=6; p=0.13) and 1000 μM
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(12.92 ± 6.24 Hz baseline 7.74 ± 4.46 Hz in the presence of 1000 μM glycine;
n=3; p=0.33) showed a non-significant trend toward decreasing frequency, these
higher concentrations also resulted in whole-cell currents and mEPSC amplitude
changes that interfered with interpretation of presynaptic changes. As a result,
these higher concentrations were not further explored. The effect of glycine
application was not assessed in T1-diabetic mice.
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Figure 5.3 Glycine has differential concentration effects on mEPSC frequency.
A. Representative trace of mEPSCs at baseline in the presence of PTX or Bic,
DTC, TTX and AP-5 (upper two traces) and in response to 30 μM glycine (n=4)
(lower two traces). B. Representative trace of mEPSCs at baseline in the
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presence of PTX or Bic, DTC, TTX and AP-5 (upper two traces) and in response
to 100 μM glycine (n=5) (lower two traces). C. Average mEPSC group frequency
and amplitude in response to 30 and 100 μM glycine in the presence of PTX or
Bic, DTC, TTX and AP-5 Statistical significance of drug application was assessed
using a paired two-tailed Student’s t-tests and * indicates p<0.05.

Glycine transport inhibitors did not change mEPSC parameters
Availability of glycine is partly controlled by GlyTs on neurons as well as on glial
cells. Both of the two known glycine transporters have been identified in the DVC
(Batten et al., 2010; Zafra et al., 1995). To test whether or not the inhibition of
these transporters would result in glycine-mediated activation of glycine
receptors, mEPSCs were measured in response to glycine transport inhibitors in
normoglycemic controls and T1-diabetic mice. Recordings of mEPSCs were
made at a holding potential of -80 mV in the presence of PTX, TTX, DTC and
AP-5 prior to and following the application of the GlyT1 inhibitor, Org 24598
lithium salt (10 μM), and the GlyT2 inhibitor, ALX 1393 (0.5 μM). In
normoglycemic mice, application of these receptors did not result in a significant
change in mEPSC frequency (21.97±4.3 events/s baseline, 18.59±3.78 Hz in
response to combined GlyT Inhibitors p=0.08; n=6; Figure 5.4 A and C). No
change in the amplitude of mEPSCs was observed in response to GlyT Inhibitors
(23.95±4.2 pA baseline, 19.31±3.1 pA in response combined GlyT Inhbitors
p=0.10). As in control mice, the mEPSC frequency and amplitude of T1-diabetic
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mice in response to GlyT1 and 2 inhibitors did not change (32.29±9.3 Hz
baseline, 27.59±9.3 Hz in response GlyT Inhibitors , p=0.16 and 20.11+3.5 pA
baseline, 22.16+4.6 pA in response to Org 24598 and ALX 1393 p=0.54; n=3;
Figure 5.4 B and C).
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Figure 5.4 GlyT1+2 inhibitors did not change mEPSC parameters. A.
Representative recording of mEPSCs in control mice at baseline, in the presence
of PTX, TTX, DTC and AP-5, (upper two traces) and in response to 1-2μM
GlyT1+2 inhbitors (lower two traces) (n=6) B. Representative recording of
mEPSCs in T1-diabetic mice at baseline, in the presence of PTX, TTX, DTC and
AP-5, (upper two traces) and in response to GlyT1+2 inhibitors (lower two traces)
(n=3) C. Average group frequency and amplitude of mEPSCs in response to
bumetanide and strychnine. D. Group average percent change from baseline
frequency in response to strychnine. A paired two-tailed Student’s t-test was
used to assess statistical significance of intragroup drug application.
Org 24598 alone did not change mEPSC parameters
GlyT1 is thought to be primarily located on glial cells to prevent glycine removal
from the synaptic cleft (Eulenburg et al., 2005). The GlyT1 inhibitor Org 24598
was used to measure the effect of GlyT1 on glycine availability at the synaptic
cleft. Recordings were taken at -80 mV in the presence of PTX, TTX, DTC and
AP-5 prior to and in the presence of Org 24598. Application of Org 24598 did not
result in a change of mEPSC parameters (24.08±6.4 Hz baseline, 24.21±5.0 Hz
in response to Org 24598 p=0.96 and 20.00 +2.6 pA baseline, 18.1+1.7 pA in
response to Org 24598 p=0.19; n=4; Figure 5.5). Potential changes in mEPSC
parameters were not measured in T1-diabetic mice.
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Figure 5.5 GlyT 1 inhibition by Org 24598 did not change mEPSC parameters.
A. Representative recording of mEPSCs in control mice at baseline, in the
presence of PTX, TTX, DTC and AP-5. B. Representative recording of mEPSCs
in control mice, in response the GlyT1 inhibitor, Org 24598, in the presence of
PTX, TTX, DTC and AP-5 C. Average frequency and amplitude of mEPSCs in
response to GlyT1 inhibitor (n=4). A paired two-tailed Student’s t-test was used to
assess statistical significance.
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Discussion
PreGlyR have been identified in other regions of the brain, and their activation
has been linked to the tonic enhancement of excitatory and inhibitory
neurotransmission (Kunz et al., 2012; Turecek and Trussell, 2001). In studies
that identified a preGlyR activation mediated increase in release probability, this
effect was found to be dependent on NKCC1 as a result of NKCC1’s function to
maintain a preterminal equilibrium potential conducive to a depolarizing influence
of Cl- influx (Kunz et al., 2012).
The result of this study using the GlyR receptor antagonist strychnine suggested
the presence of preterminal glycine receptors. The increase in mEPSC frequency
in the absence of a change in amplitude in response to strychnine suggested that
glycine receptors are tonically active to lower glutamate release probability at
terminals contacting DMV neurons. This result, therefore, would argue against a
conventional role of preGlyRs in the DVC (in other regions of the brain preGlyRs
inhibition causes a decrease in release probability of neurotransmitters).
The results of this study showing an increase in mEPSC frequency (suggesting
and increase in the release probability of glutamate) led to hypothesis that
preterminal Cl- influx through preGlyR would hyperpolarize the preterminal
membrane. To understand the differences in preGlyR function between previous
studies and the present one, the effect of NKCC1 inhibition and subsequent
strychnine inhibition was investigated. The NKCC1 inhibitor, bumetanide, did not
have an effect on mEPSC frequency or amplitude. The strychnine-dependent
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increase in mEPSC frequency persisted despite the presence of bumetanide. In
previous studies, the effect of strychnine was abolished in the presence of the
NKCC1 inhibitor bumetanide (Kunz et al., 2012). The results of this study argue
that NKCC1 does not modulate preGlyR-dependent effects and are consistent
with preGlyR underlying alternative rules of engagement.
Further experiments will need to be conducted to investigate such mechanisms.
One possible player may be the potassium K+-Cl- co-transporter 2 (KCC2), which
transports chloride outwardly and maintains a lower Cl- equilibrium potential. As
a result, during its developmental increase, it shifts chloride flux on postsynaptic
currents from depolarizing to hyperpolarizing (Kunz et al., 2012; Payne et al.,
1996; Stil et al., 2009). A future study examining the effect of KCC2 on
strychnine-mediated effects would seem like a next logical experimental step.
Additionally, in previous studies the preGlyR was linked to a voltage-dependent
calcium channel (VDCC) (Kunz et al., 2012; Turecek and Trussell, 2001). A
future study addressing this link between preGlyR and VDCC would also be of
interest in the context of preGlyR at terminals contacting DMV neurons.
Therefore, Cd+ could be used to study the Ca2+ dependence of preGlyR function.
Based on previous studies, it was hypothesized that blocking GlyTs would result
in an increase in the amount of glycine available to bind to preterminal receptors.
Strychnine antagonist studies suggested an increase in the release probability
through the inhibition of preGlyRs. It was therefore reasoned that a GlyT
inhibition-mediated increase in ambient glycine concentration, should enhance
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activation of preGlyR and subsequently decrease glutamate release probability.
This negative result argues that these transporters do not cause a sufficient
increase in glycine to change its saturation level at preGlyRs. Alternatively, the
excess glycine made available by GlyT inhibition also binds to NR3-subunit
containing NMDA receptors to counterbalance the effects of glycine on GlyR (see
further discussion below).
A localization of GlyT2 specific to glycinergic neurons would be expected to
prevent the recycling of glycine, decreasing its vesicular release and ultimately
making less glycine available. The specificity of GlyT1 and Glyt2 on glial cells
and glycinergic neurons, respectively, has been challenged for some regions in
the brain (Aroeira et al., 2013; Cubelos et al., 2013). The effect of GlyT1
inhibition alone was measured to rule out that GlyT2 localization on glycinergic
neurons counterbalances the GlyT1 function, and mask the effects of GlyT1.
(Zafra et al., 1995; Zafra et al., 1997b). The GlyT1 inhibitor Org 24598 lithium
salt, however, had no effect on mEPSC parameters measured in DMV neurons
from control mice. This result argues that GlyT1 does not have a significant
impact on the availability of glycine on preGlyR in the DVC. Responses to Org
24598 were not measured in T1-diabetic mice. An upregulation of these
transporters could be tested in T1-diabetic mice.
It remains possible that when applying exogenous glycine in the presence of a
GlyTs the inability to uptake glycine would lead to a potentiation of glycine
mediated preGlyR response. A comparison between the glycine mediated effect
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in the presence and absence of GlyT inhibitors could be tested to better ascertain
the physiological relevance mediated by these transporters. A glycine response
curve to exogenously applied glycine, in the absence of inhibitors, would be
necessary.
Experiments were conducted to establish an agonist response curve for glycine,
but the results could not differentiate clearly between pre- and postsynaptic
GlyRs and possible confounding effects mediated by NR3 subunit-containing
NMDA receptors. NR3 subunit-containing diheteromeric NMDA receptors can be
activated by glycine alone, in the absence of other agonists, and are not blocked
by NR2 subunit-containing receptor antagonists such as AP-5 and/or MK-801
(Low and Wee, 2010; Paoletti and Neyton, 2007). Pharmacological manipulation
of the NR3 subunit remains limited and further experiments would be necessary
to determine whether or not these subunits are involved in mediating the small
but significant increase in mEPSC frequency observed at a low glycine
concentration (30 μM). Glycine induced a significant decrease in mEPSC
frequency, without whole-cell current induction or amplitude change, at a
concentration of 100 μM. The higher concentrations tested, 300 and 1000 μM
caused a significant inward whole-cell current.
It has been argued that glycine is in the extracellular space surrounding of the
synaptic cleft to allow constitutive activation and co-activation of glycine and
NMDA receptors, respectively. This notion, however, has been challenged with
the argument that glycine is readily cleared from the extracellular space and the
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synaptic cleft through GlyTs (Berger et al., 1998; Bergeron et al., 1998). These
clearing mechanisms have produced estimates of glycine concentrations around
transporter microdomains that fall below saturation levels of NMDA receptors.
NR3-containing NMDA receptors, therefore, create a potential confounding factor
in glycine mediated effects. These subunits can be solely activated by glycine
and do not show the AP-5 sensitivity seen in NR2 subunit-containing NMDA
receptors. The presence of NR2-lacking NMDA receptors in the brain, however,
has not been conclusively demonstrated.
The increase in mEPSC frequency at a low glycine concentration (30 μM) may
be the result of NR3 subunit-containing NMDA receptor activation. Based on the
current study, glycine might be predicted to have opposite effects on the
membrane potential by acting at preGlyR and NR3-subunit containing preNMDA
receptors. While glycine acting on NR3-subunit containing preNMDA receptors
would be expected to facilitate glutamate release, glycine acting on preGlyR
would be expected to lower glutamate release probability. These opposing
effects may mask the significance of either receptor and cannot be appreciated
from the studies conducted. Picrotoxin was used throughout most of these
studies. Since picrotoxin blocks GlyR co-assembled as α- and β-subunits, their
effect on preterminal glutamate cannot be appreciated by these studies and
changes in subunit distribution could account for the differences in the percent
change of frequency in response to strychnine in T1-diabetic mice.
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The pharmacological approaches to address this question remain limited. An
NR3 subunit specific antagonist that allows expression of AMPA-mediated
postsynaptic EPSCs, which were used as primary outcome measures, is not
available (Paoletti and Neyton, 2007). The agonist glycine could be used in the
presence of strychnine and/or GlyT inhibitors to investigate the action of glycine
on NR3 subunit containing preNMDA receptors. D-serine is endogenously
biosynthesized enantiomer of the amino acid serine that binds to the NMDA
receptor glycine binding sites (Mothet et al., 2000). D-serine is not thought to be
transported by glycine transporters or to activate GlyR (Betz et al., 2006;
Supplisson and Bergman, 1997). It could therefore be used in conjunction with
glycine to confirm NR3 subunit-mediated glycine effects and provide a better
understanding the two GlyTs may have on glycine availability. Specific agonists
for GlyR are lacking and limit the understanding of their endogenous saturation
state. A cross-talk between NR3-subunit containing and GlyR on preterminal
membranes could be important in regulating glutamate release more tightly.
Understanding the role this potential cross-talk plays on glutamate release would
be interesting both in a physiological as well as pathological context (for more
elaborate discussion see general discussion in Chapter 6).
The mEPSC frequency percent change in normoglycemic mice in response to
strychnine was 36.97±24.1% while it was 60.05±16.2% in T1-diabetic mice.
Increasing the number of neurons studied for these groups could reveal whether
or not these differences are statistically significant. For a more complete
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discussion on possible interpretations of significance in this result see general
discussion in Chapter 6.
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Chapter 6: General Discussion

Review of major findings
Preterminal NMDA receptors were previously established to be present in
other regions of the brain, but their existence and functional significance of
neurotransmitter release had not previously been looked at in the DVC (Aorti
1994; Berretta 1996, Marty and Glitsch 2002). Chapter 3 of this dissertation
establishes the presence of preNMDA receptors on terminal contacts to the
DMV, and their functional contribution to the tonic release of glutamate onto
neurons within this nucleus. While their presence facilitated glutamate release,
results within this dissertation argue against their presence on GABAergic
terminals and functional significance to the release of GABA.
It was hypothesized that augmented facilitation by these receptors,
possibly through increasing their expression, may lead to the enhanced
glutamate release and excitatory drive onto DMV neurons (mEPSCs frequency
increase) occurring in T1-diabetic mice.
NMDA receptors, including preNMDA receptors, were explored for their
potential participation in pathological network changes in T1-diabetic mice in
Chapter 4. Previous findings by Zsombok, showing an increase in mEPSC and
sEPSC frequency in the absence of a change in amplitude, of T1-diabetic mice
could be confirmed. NMDA dependent mechanisms underlying these changes in
the release probability of glutamate were explored in Chapter 4.
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Electrophysiological recordings of the DMV revealed that when NMDA
receptors were blocked in the DVC of control and T1-diabtic mice, T1-diabtetic
mice had a greater relative decrease in the frequency of sEPSCs. This result
suggested a greater NMDA receptor mediated effect of glutamate release. The
decrease in frequency in the absence of amplitude changes was consistent with
a presynaptic modulation of NMDA receptors and supported their involvement in
the underlying mechanisms of pathological changes in T1-diabetic mice.
The hypothesis that preNMDA receptors mediated augmented glutamate
release onto DMV neurons of T1-diabetic mice could not be confirmed. While
excitatory neurotransmission in both animal groups was tonically facilitated by
preNMDA receptors, the relative contribution was not altered in T1-diabetic mice.
Consequently, postsynaptic NMDA receptor responses on presynaptic
(NTS) neurons were investigated. An increase in the NMDA-induced whole-cell
current and current density was observed and the current voltage steps revealed
that this increase in whole-cell current and current density of T1-diabetic mice
occurred at voltage potentials consistent with NMDA mediated responses.
Using single-cell PCR, an upregulation of NMDA subunit transcripts in a
subpopulation of glutamatergic neurons could be demonstrated. Responses in
these neurons showed a decrease in standard error of whole-cell current
responses and current densities. When eliminating the identified VGLUT2+
neurons from the total NTS population, there was a significant difference
between the current densities of control animals between the VGLUT2+
population and the total population.
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These data, however, were not presented independently, because singlecell PCR was unsuccessful on many of these neurons. Their phenotype is
therefore not known and they could be VGLUT2+ neurons especially since this
population was biased towards non-GABA neurons by using GIN mice. GIN mice
were used and electrophysiological recordings were typically targeted to those of
non-GABA neurons. These neurons make up a large population of cells in the
NTS.
NTS neurons are known to make direct glutamatergic synaptic
connections to the DMV neurons. This result is therefore consistent with an
NMDA mediated response eliciting an enhanced excitatory drive in NTS neurons.
Given that the NTS and DMV form a direct functional glutamatergic connection,
this increase in the excitatory drive would further be predicted to enhance
excitatory neurotransmission on DMV neurons and is consistent with an the
observed increase in sEPSCs observed on DMV neurons (Travagli 2011).
NMDA receptor modulation of whole-cell current (WCC) responses could
be due to changes in the number of receptors present, reshuffling of receptor
subunits, and/or receptor trafficking (Collingridge et al., 2004; Traynelis et al.,
2010).
The total number of receptors should be reflected by the expression of the
NR1 subunits, as this is the necessary receptor subunit for functional NMDA
receptors (Traynelis et al., 2010). Protein expression of the NR1 subunit between
control and T1-diabetic mice but was not statistically significant although we were
able to observe trend towards an increase in NR1 expression in T1-diabetic
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mice. Gene expression changes were analyzed for all seven NMDA receptor
subunits, but no differences between control and T1-diabetic mice were observed
in any of these subunits. This result likely reflects a more global problem in
identifying changes between groups of animals in a heterogeneous population of
cells (but see discussion below).
Preterminal mechanisms in control and T1-diabetic mice
The experiments conducted throughout this dissertation were unable to
identify changes in synaptic plasticity at the presynaptic terminal suggested by
the increase in mEPSC frequency of T1-diabetic mice. Nonetheless, the function
of preNMDA receptors to facilitate glutamate release onto DMV neurons remains
intact. Consequently, it could be conceivable to identify and manipulate such
specific preterminal mechanisms. With the prediction that enhanced vagal output
leads to a physiological response of lowering blood glucose concentrations, by
extension, the NMDA-mediated enhancement of excitatory neurotransmission
would serve as counter-regulatory mechanism in T1-diabetic mice. If this is
indeed the case, driving this process may serve as a potential site to
pharmacologically interfere with this process during acute states of
hyperglycemia that can lead to a number of different complications. Therefore
gaining a better understanding about the specific mechanisms involved in
preterminal facilitation would be valuable.
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PreNMDA receptor subunits effects in the DVC
Pharmacological limitations did not allow a full profile of preNMDA
receptors to be made, but the use of Zn2+ suggested that NR2A subunits are
most likely involved in the tonic modulation of glutamate release mediated by
NMDA receptors (Paoletti et al., 1997). NR2C/NR2D or NR3 subunit specific
antagonists are not currently available. NR3 subunits are not inhibited by AP-5 or
activated by NMDA although triheteromeric receptors are thought to be affected
by both (Paoletti and Neyton, 2007).
PreNMDA receptors containing NR2C and NR2D or NR3-subunit are less
permeable to Ca2+ than NR2A and NR2B subunit containing receptors with NR3subunit containing nearly completely lack Ca2+ permeability (Cull-Candy and
Leszkiewicz, 2004; Henson et al., 2010; Paoletti and Neyton, 2007). The subunit
identity is of particular interest for understanding the mechanisms for eliciting an
increase in the probability of glutamate release. Therefore, these subunits and in
particular the NR3-subunit at the preterminal membrane, that mediate this
change towards indirect modulation of Ca2+ influx. The lack of Mg2+ sensitivity
make them a likely NMDA-receptor subunit to be involved in tonic modulation of
glutamate release and their presence in preNMDA receptors has been shown
(Larsen, Philpot, Corlew 2011). Due to their concomitant lack of Ca2+ influx, it
would be predictable that when searching for mechanistic underpinnings of
glutamate release to look at more indirect increases in the level of Ca2+. A local
depolarization of the preterminal membrane could subsequently activate VDCC
channels.
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Cross-talk of preNMDA- and preGlyR receptors in the DVC in the context of
development and synaptic plasticity
While antagonist approaches remain limited, the agonist glycine can
activate these receptors and has therefore presented itself as an agonist to be
used in studies of preNMDA NR3-subunit receptors (Henson, Philphot 2011).
The prominent opinion holds that D-serine acts as an agonist on this receptor
subunit, although some controversy regarding this opinion has been sparked
(Nilsson, Sundstrom 2007; Yao and Mayer 2006, Chatterton, Zhang, 2002).
Consequently studies looking into NR3-subunit containing receptors used glycine
as an agonist. The GlyR specific antagonist strychnine was used in these studies
to prevent potential interference of results underlying preGlyR activation. This
experimental approach revealed a strychnine sensitive response suggesting the
presence of preGlyR. These results were particularly interesting for further
exploration, because they suggested a cross talk at the preterminal membrane
between preGlyR and preNMDA receptors.
Understanding the role of NR3A-subunit containing receptors is of
particular interest due to their high expression levels in the DVC as identified by
mRNA expression using NanoSting®. While the subunit expression was not
altered in T1-diabetic mice, it showed the highest expression levels of any of the
subunits other than the obligatory NR1 subunit. In other regions of the brain the
primary consensus holds that this subunit undergoes a developmental increase
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in expression until P4-P10, but then drops to low levels in adulthood (Henson et
al., 2010). In the amygdala, however, highest expression of this subunit is
observed at adulthood (Wong et al., 2002). It cannot be assumed that NR3
expression is highest at the adult stages measured throughout these
experiments. It does provide justification to look at expression changes for this
subunit throughout development. Regardless of its developmental profile, its high
adult gene expression argues that this subunit plays a prominent role in the DVC.
Preliminary results obtained from presynaptic studies suggest that this subunit
may potentially be located at preterminal membranes to facilitate glutamate
release (see Chapter 5).
As prior, pharmacological limitations of NR3 antagonists and specific
glycine receptor agonists makes studying these receptors in isolation limited (see
Chapter 5 discussion for additional pharmacological approaches). The role of
these receptors and the role GlyTs play in maintaining an appropriate excitatory
and inhibitory balance under physiological as well as pathological states presents
itself as an interesting question.
Preterminal results suggest that GlyR inhibition of preterminal glutamate
may be enhanced in T1-diabetic mice (greater percent change of mEPSC
frequency). It has recently been established that glycine and glutamate are
colocalized in presynaptic terminals. Excitatory stimulation elicits a release of
stored glycine and has suggested that glycine and glutmate are coreleased
(Muller, Bergeron, 2013). If present in the DVC, this form of corelease could
present itself as a form of preterminal balance between inhibitory preGlyR and
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excitatory preNMDA receptor function. Modulating this balance could thus be the
function of glycine-activated preNMDA receptors and preGlyR moving closer or
further away from one another. Their proximity to each other may significantly
affect the preterminal consequence of circulating glycine and underlie a
compensatory mechanism or exacerbate preterminal hyperexcitability seen in
T1-diabetic mice. Modulation of GABAergic release was not tested as part of
these studies, but should be conducted in the future form a more complete
picture of a preterminal excitatory-inhibitory balance as a function of preGlyR and
preNMDA receptor cross-talk. Similarly, these cross-talks may balance excitatory
and inhibitory neurotransmission at postsynaptic membrane receptors in the
DVC.
Beyond the pharmacological approaches and limitations discussed as part
of Chapter 5, ultrastructural and/or knock-out studies, may aid in shedding light
on these hypotheses. It would be interesting whether these two receptors diffuse
across the membrane in a manner that allows them to move closer or further
apart from one another and therefore potentially alter the effective concentration
of glycine observed at each receptor. This in turn could alter the balance of
glutamate release at the terminal. The use of electron microscopy could,
therefore, not only support the presence of these two receptors on glutamatergic
preterminal membranes, but may detect concerted trafficking as a function of T1diabetes induced synaptic plasticity.
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NMDA receptors on NTS neurons of normal and T1-diabetic mice
While the results of this study establish enhanced NMDA-mediated wholecell currents and current densities, they open up a large array of questions that
remain to be explored further. Changes in NMDA receptor mediated responses
could be due to changes in the number of receptors present, reorganization of
receptor subunits, and/or receptor trafficking (Collingridge et al., 2004; Traynelis
et al., 2010).
The total number of receptors should be reflected by the expression of the
NR1 subunits, as this is the necessary receptor subunit for functional NMDA
receptors (Traynelis et al., 2010). Protein expression of the NR1 subunit between
animal groups but was not statistically significant difference although we were
able to observe a trend towards an increase in NR1 expression in T1-diabetic
animals.
Limitation of whole slice analysis in the of subpopulation specific changes
What must be taken into consideration, however, are experimental
limitations of isolating solely the NTS region of the DVC. Tissue extracts typically
also contained other areas including the DMV and the area postrema (AP) along
with other prominent connections to the NTS. No recordings were conducted in
the AP, and evidence for or against NMDA receptor changes between control
and T1-diabetic animals cannot be discussed.
Electrophysiological recordings in the DMV did not suggest changes of
postsynaptic receptors based on changes in amplitude or decay time, although
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no conclusive studies to test this hypothesis were conducted. In all experiments,
voltage clamp recordings of EPSCs were made at -60 or -80 mV. At these
potentials Mg2+ dependent voltage block of NMDA receptor would remain largely
intact (unless diheteromeric NR3-subunit containing NMDA receptors make up a
substantial NMDA receptor population) and prevent interpretation of postsynaptic
receptors. Based on the enhanced presynaptic excitatory neurotransmission an
increased expression of NMDA receptors, possibly as a consequence of LTPNMDA
and LTDNMDA –like mechanisms, on these neurons would not be surprising
(Paoletti et al., 2013).
In the context of a failure to observe changes in NR1 expression levels,
however, a lack of increased expression in the DMV and the AP could limit the
needed sensitivity to observe changes specific only to NTS regions of the DVC.
Additionally, the NTS consists of a heterogeneous population of cells and
NR1 expression was hypothesized only to be enhanced in the glutamatergic
population (no change in IPSCs between control and T1-diabetic mice). Given
that only a subpopulation of neurons in the NTS are of the VGLUT2+ phenotype,
limitations of sensitivity to protein expression in the total NTS neuron population
would persist. It could even be possible that other NTS phenotypic populations’
exhibit decreased NMDA expression patterns.
Addressing the correlation of NMDA expression in other phenotype and
between animal groups could be interesting both in a physiological and
pathological context. Overall the identification of increased whole-cell currents
argues for a greater NMDA mediated component of excitatory
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neurotransmission, which would, in the presence of sufficient glutamate, be
expected to lead to more prolonged membrane depolarization (Traynelis et al.,
2010). In the dorsal vagal complex this could be result of converging inputs of the
various metabolic, hormonal and synaptic inputs interpreted by the nuclei of the
DVC.
Apart from the VGLUT2+ phenotype, a VGLUT3+ glutamatergic
phenotype has also been shown to have high expression in NTS neurons.
VGLUT2 and VGLUT3 do not colocalize in terminals of the NTS and are
therefore thought to be distinct population. While either glutamatergic phenotype
would be expected to lead to an enhanced excitatory neurotransmission in
synaptically connected DMV neurons, an enhanced NMDA receptor mediated
excitatory drive in GABAergic neurons would result in an inhibitory downstream
effect. Moreover, it is possible that the glutamatergic neurons in question do not
directly synapse onto DMV neurons but rather on local GABA or other network
neurons. Both of these possibilities could result in an opposing functional
outcome by enhancing the inhibitory drive to DMV neurons, but this form of
plasticity would also be expected to modulate the release of GABA and an
increase IPSC frequency. The failure to detect such an increase, therefore,
argues against a presynaptic enhancement in GABAeregic neurons. As a result
the most likely conclusion is that increased NMDA-mediated postsynaptic
currents in VGLUT2+ positive neurons enhance excitatory neurotransmission.
Overall the array of phenotypes that could have vastly distinct changes in
NMDA receptor expression and resultant electrophysiological responses, limits
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the interpretation of protein expression or mRNA expression experiments
conducted in slices of the DVC. Tissue extracts typically also contained other
areas including the DMV and the AP. No recordings were made in the AP and
potential NMDA receptor changes in T1-diabetic mice cannot be discussed as
part of these studies.
Single-cell approached that can directly link electrophysiological
responses with expression changes are as well as specific neuronal populations,
would provide a better understanding the overall effect on excitatory
neurotransmission. In studies of this dissertation, this approach was used for
VGLUT2+ phenotypic identification. Apart from a VGLUT2+ phenotype, VGLUT3
expression has also been identified in the NTS and the two transporters are not
thought to co-localize and therefore to make up independent populations of
glutamatergic neurons (Lin et al., 2004; Lin and Talman, 2005). A primer
VGLUT1 and VGLUT3 was not used to probe for this transporter, but an
experiment to this effect could be conducted in the future. VGLUT1 has been
shown to be expressed in the NTS but to a much more limited extent in
subregions of the NTS (Hermes et al., 2013; Lin, 2009; Lin et al., 2004; Lin and
Talman, 2005). Ideally expression of all three VGLUTs could be looked at with
VGLUT1 and VGLUT3 being used as additional markers that should be able to
target most glutamatergic NTS neurons. Apart from phenotypic identification it
would be of particular interest in the context to link electrophysiological
responses to quantitative changes of NMDA receptors and its subunits. Both
TaqMan based PCR or single cell nCounter® NanoString has been shown to
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have the necessary sensitivity to detect quantitative expression changes at the
level of single-cells (Stahlberg, Bengtsson 2010).
Subunit specific modulation in the DVC
In addition to changes in the number of receptors, subunit changes may
be involved in modulating NMDA receptor responses. As discussed in Chapter 1,
NMDA receptor subunits confer distinct kinetic profiles on NMDA receptors.
To reiterate briefly, decay times span a ~50 fold range in the order NR2A<
NR2B<NR2C<NR2D from fastest to slowest (Cull-Candy and Leszkiewicz,
2004). Mg2+ sensitivities correlate with Ca2+ permeability and are high for
NR2A/B subunits, low for NR2C/D-subunits and do not play a role in NR3 subunit
containing receptors (Ciabarra et al., 1995; Paoletti and Neyton, 2007). NR3
subunits, however, are not activated by NMDA or blocked by AP-5 and can
therefore only be discussed as having an involvement in triheteromeric receptors
(NMDA receptor dependent changes were observed in response to these
pharmacological agents (Henson et al., 2010; Paoletti and Neyton, 2007).
The protein expression of these subunits was not tested but quantitative
subunit expression changes were analyzed at the level of mRNA using
NanoString®. No gene expression changes were observed between control and
T1-diabetic mice. These results are subject, however, to the same limitation of
brain slices containing heterogeneous cell populations of cells. More globally it
argues that expression changes of pathological states of the DVC needs to be
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investigated in phenotype specific cell populations. The subunit specific
discussion is targeted to changes in specific phenotypic populations.
Based on electrophysiological current-voltage responses observed in this
study, subunit switches in T1-diabetic animals were predicted. Both animal
groups showed a nonlinear current voltage response suggestive of a Mg2+
dependent voltage sensitivity, but maintained a substantial inward current at
negative potentials normally exhibiting Mg2+-dependent block (Nowak et al.,
1984). This limited voltage sensitivity in NTS neurons at baseline conditions
(figure 4.6.B) is consistent with high NR3-subunit expression in the DVC as
indicated by mRNA expression levels.
Current-voltage responses showed a trend towards increased voltage
sensitivity in T1-diabetic mice and some neurons in a proportion of cells in T1diabetic mice. This was enhanced in some neurons to a greater proportion in T1diabetic mice, but phenotypic identifications were not made in sufficient number
of neurons to link them to a particular phenotype. Increased voltage sensitivity
would argue for an increase in magnesium sensitivity and a greater proportion of
NR2A/B subunits over NR2C/D or NR3 subunits (Henson et al., 2010; Wyllie et
al., 2013). During early development NR2B are thought to be the primary subunit
type present in the brain and are gradually replaced by NR2A subunits making
these subunits the primary subtype during adulthood (Monyer et al., 1994).
Although adult mice were used in these studies, it is possible that under
conditions of synaptic plasticity, a juvenile-phenotype becomes reinstated and
allows the nucleus greater freedom to modulate its circuitry under pathological
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states, possibly in an attempt to mount counter-regulatory responses such as
decreasing liver gluconeogenesis.
The NR2B specific antagonist, Org 25-6981 (Tocris), could be used to
address this question further. To address alterations in Ca2+ permeability, Ca2+
imaging studies could be conducted and may provide supporting evidence for
subunit substitutions of subunits with low Ca2+ permeability. The NR3 subunit is
essentially impermeable to Ca2+, when expressed only in conjunction with NR1
subunits. While the expression of NR1/Nr3 subunits has been shown in
heterologous expression systems to make functionally ion conducting channels,
their expression in vivo is still being questioned. When expressed with NR2
subunits, however they are thought to exist as triheteromers in vivo and decrease
the conduction when compared to NR/1NR2 containing of NMDA receptors. Ca2+
imaging studies in conjunction to the subunit specific pharmacological agents
that are available aid in strengthening support for the significance in synaptic
modulation as a function of the NR3 subunit (Henson et al., 2010; Pachernegg et
al., 2012).
Receptor trafficking and LTP/LTD dependent synaptic plasticity
Finally, receptor trafficking from internal stores as well as from
extrasynaptic sites into the PSD may contribute to altered excitatory inputs
observed in studies throughout this dissertation. Trafficking can occur from
internal as well as from extrasynaptic sites. Whole-cell currents were targeted to
activate all NMDA receptor populations on NTS neurons, and trafficking of

130

extrasynaptic receptor as a result of T1-diabetes would be expected to activate
similar population of NMDA receptors and lead to similar whole-cell current
responses. Trafficking from internal, however, has been shown previously and
would introduce a new receptor population to the membrane to increase current
amplitudes. Consequently, receptor trafficking from internal stores presents itself
as a plausible explanation of enhanced NMDA receptor function even in the
absence of expression changes.
The frequency of sEPSC in downstream neurons may be more sensitive
towards detecting changes in trafficking given that only receptors in the PSD or
perisynaptic receptors would be expected to alter firing properties. Therefore
receptor trafficking from extrasynaptic sites into to the PSD could explain
increased sensitivity of AP-5 on sEPSCs (a greater relative percent decrease in
frequency in response to AP-5).
The concept of receptor trafficking becomes more interesting in the
context of LTP and LTD. Although studies to this effect were not conducted as
part of this dissertation, precedent for changes in both of these mechanism in T1diabetes exists and opens up a large array of future experimental approaches
(Artola, A 2005). In the hippocampus for example, LTP and LTD are of
comparable magnitude in T1-diabetic animals, but long term depression is
facilitated and LTP is inhibited. These studies were conducted in rats maintained
hyperglycemic for multiple months (Artola et al., 2005). It would be interesting to
test whether responses over prolonged hyperglycemia would lead to similar
changes in LTP and LTD mechanisms. Combining such studies with more short
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term studies would be interesting in understanding whether these changes
persist long term or are rather transient changes for a system in flux. Signaling
mechanisms of LTP and LTD have been extensively studied and some of their
players may eventually serve as targets for therapeutic approaches. In particular
the NR3-subunit is thought to play a prominent role in LTD mechanisms, and
would be an interesting player to focus on in studies of T1-diabetic mice in the
DVC. Given that this subunit generally shows low expression in many other
regions of the brain, but high expression in the DVC, future pharmacological
advances in this subunit may prove themselves as relatively specific therapeutic
agents for the DVC.
Final Conclusion
While NMDA mediated effects on normal physiological function in the DVC
have been well established, this study is the first to identify preNMDA receptors
on terminal contacts to DMV neurons and changes in NMDA receptor function
under pathological conditions of T1-diabetes in the DVC. Evidence throughout
this dissertation provides support that changes in NMDA receptors contribute to
the mechanisms of augmenting excitatory neurotransmission in the DVC. The
altered receptor responses in this dissertation, as a result of metabolic
dyshomeostatis in pathological states of T1-diabetes, would argue for the need of
more expansive studies. It remains unclear if this response serves a
compensatory mechanism, possible by lowering gluconeogeneis or whether this
is a physiological response spun out of control.
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The predicted well known mechanism of synaptic plasticity, such as LTP,
would be expected to strengthen and possibly alter synaptic circuitry and bestow
urgency on the need to better understand its processes in the DVC. If the DVC
preserves its ability to modulate synaptic circuitry, it may potentially serve as a
target region to mount pharmacological counterregulatroy responses.
The high expression of an NMDA receptor subunit that lowers ionic
conductance, notably of Ca2+, is only minimally sensitive to Mg2+ and can be
activated by glycine, should be explored further. This subunit may change the
rules of synaptic conductance mediated by NMDA receptors in the DVC while
possibly communicating closely with Glycine mediated inhibitory drives. It will be
important to understand these mechanisms as NR3A subunit expression is
thought to be low in adult animals in other regions of the brain. It may prove itself
as a potential relatively specific pharmacological target.
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Appendices

Appendix 1: List of Abbreviations
AMPA- α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ACSF- Artificial cerebrospinal fluid
ABD- Agonist binding domain
AP- Area prostrema
AP-5- DL-2-Amino-5-phosphonopentanoic acid
Bic- Bicuculline methiodide
CaMKII- Calcium/calmodulin-dependent protein kinase II
CNQX- 6-Cyano-7-nitroquinoxaline-2,3-dione
CTD- C-terminus domain
DMV- Dorsal motor nucleus of the vagus nerve
DVC- Dorsal vagal complex
DTC- d-tubocurarine chloride
EPSC- Excitatory postsynaptic current
fwd- forward
IPSC- Inhibitory postsynaptic current
HFS- high frequency stimulation
Hz- hertz
GlyR- Glycine receptor
GlyT- Glycine transporter
LTD- long term depression
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LTP- long term potentiation
mEPSC- miniature EPSC
mGLUR- metabotropic glutamate receptor
min- minutes
mIPSC- miniature IPSC
MK-801- -(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
hydrogen maleate or dizocilpine
NMDA- N-methyl-D-aspartic acid
NTD- N-terminal domain
NTS- Nucleus of the solitary tract
P- Postnatal
preGlyR- presynaptic glycine receptor
preNMDA- presynaptic NMDA
PPr- Paired-pulse ratio
PSD- postsynaptic density
PTX- Picrotoxin
rev- reverse
RIN- RNA integrity number
RPM- revolution per minute
T1-diabetic- Type 1 diabetic
TMD- transmemrane domain
TTX- Tetrodotoxin
s- seconds
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sEPSC- spontaneous EPSC
sIPSC- spontaneous IPSC
STZ- Streptozotocin
VGLUT- Vesicular glutamate transporter
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Appendix 2: Equipment used for Electrophysiological data acquisition and
brainstem slice preparation
List of Equipment
Vibrating Microtome (Vibratome 1000 Plus)
Pipette Puller (Sutter P-87)
Vibration Isolation Table (TMC)
Microscope (Olympus BX51WI)
Digitizer (Digidata 1320A and 1440A)
Patch-Clamp Amplifier (Axopatch 200B or Multiclamp 700B)
Signal timer for electrical stimulation (Master-8)
Neuro-corder (Model DR-484)
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Appendix 3: Codeset for NanoString based experiments
Gene
Name
Abcc8
Actb
Dbh
Gabra1
Gabra4
Gabrd
Gabrg2
Gad1
Gad2
Gapdh
Gck
Glra1
Glrb
Glul
Gria1
Gria2
Gria3
Gria4
Grin1
Grin2a
Grin2b
Grin2c
Grin2d

Gene
NanoString Probe ID
Name
NM_011510.3:1740
Grin3a
NM_007393.3:1138
Grin3b
NM_138942.3:254
Hprt
NM_010250.4:905
Insr
NM_010251.2:3340
Itgam
NM_008072.2:475
Kcna1
NM_177408.5:1613
Kcnq2
NM_008077.4:3090
Mag
NM_008078.2:769
Nr3c1
NM_001001303.1:890 Pnmt
NM_010292.4:862
Ppif
NM_020492.3:622
Rbfox3
NM_010298.5:704
Scn8a
NM_008131.3:2145
Slc17a6
NM_001252403.1:2476 Slc17a8
NM_001039195.1:300 Slc2a4
NM_016886.3:390
Slc32a1
NM_001113180.1:1274 Syn1
NM_008169.2:492
Th
NM_008170.2:4080
Ubc
NM_008171.3:6340
Vdac1
NM_010350.2:2720
NM_008172.2:1201
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NanoString Probe ID
NM_001033351.1:1332
NM_130455.2:2030
NM_013556.2:30
NM_010568.2:8314
NM_001082960.1:3025
NM_010595.3:5725
NM_001003824.1:660
NM_010758.2:116
NM_008173.3:1800
NM_008890.1:535
NM_134084.1:534
NM_001024931.2:2700
NM_001077499.1:8560
NM_080853.3:2825
NM_182959.3:2275
NM_009204.2:275
NM_009508.2:2616
NM_013680.3:2930
NM_009377.1:235
NM_019639.4:21
NM_011694.4:562

Appendix 4. Glucose concentrations of T1-diabetic animals used for
experiments

T1-diabetic mice used for experiments in Chapter 4
sEPSCs T1-diabetic
Date of experiment
5/19/2011
4/21/2011
4/9/2011
4/9/2011
4/9/2011
4/9/2011
4/4/2011
3/16/2011
3/15/2011
3/15/2011
3/14/2011
3/14/2011
1/10/2010
1/11/2011
1/10/2011
1/9/2011
12/9/2010
1/24/2011
1/11/2011
1/9/2011

Cell
6
3
1
3
10
10
1
2
3
4
1
1
5
3
2
3
3
2
1
1
group average (cells)
group average (animals)
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Glucose conc.
444
596
600
600
600
600
532
600
600
600
600
600
584
579
584
600
575
600
579
600
583.65
573.64

mEPSCs T1-diabetic
Date of experiment
3/14/2011
4/22/2011
4/21/2011
4/21/2011
3/15/2011
4/4/2011
4/9/2011 animal 1
4/9/2011 animal 2
5/19/2011
5/19/2011
5/27/2012
5/27/2012
5/4/2012
5/4/2012
5/4/2012
6/27/2012
7/6/2012
5/18/2011
5/18/2011
5/18/2011

Cell
4
4
6
5
5
4
5
14
1
2
1
2
1
3
3
9
2
1
2
4
group average (cells)
group average (animals)
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Glucose conc.
600
541
596
596
600
582
600
600
444
444
600
600
442
442
442
335
461
600
600
600
536.25
538.54

sEPSC with AP-5 application T1-diabetic
Date of experiment
Cell
1/10/2010
5
1/11/2011
3
1/10/2011
2
1/9/2011
3
12/9/2010
3
1/24/2011
2
group average (cells)
group average (animals)
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Glucose conc.
584
579
584
600
575
600
587.00
587.60

mEPSC with AP-5 application T1-diabetic
Date of experiment
Cell
3/14/2011
4
4/22/2011
4
4/21/2011
6
4/21/2011
5
3/15/2011
5
4/4/2011
4
4/9/2011 animal 1
5
4/9/2011 animal 2
14
5/19/2011
1
5/19/2011
2
group average (cells)
group average (animals)
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Glucose conc.
600
541
596
596
600
582
600
600
444
444
560.30
566.14

WCC Currents and IV-responses T1-diabetic
Date of experiment
Cell
Glucose conc.
4/22/2013
1
461
4/22/2013
2
461
4/22/2013
3
461
4/22/2013
4
461
4/22/2013
5
461
4/22/2013 animal 2
6
600
4/22/2013 animal 2
7
600
4/22/2013 animal 2
8
600
4/22/2013 animal 2
9
600
4/22/2013 animal 2
10
600
4/27/2013
1
461
4/27/2013
2
461
4/27/2013
4
461
5/15/2013
1
505
5/15/2013
2
505
5/15/2013
3
505
5/15/2013
4
505
5/16/2013
1
407
5/16/2013
2
407
5/16/2013
3
407
6/9/2013
2
477
group average (cells)
495.52
group average (animals)
485.17

Table 8.
Protein Expression NR1 T1-diabetic
Animal
T1-diabetic 1
T1-diabetic 2
T1-diabetic 3
T1-diabetic 4
T1-diabetic 5
T1-diabetic 6
group average (animals)
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Glucose conc.
491
600
429
600
600
434
525.67

Protein Expression NR1 T1-diabetic
Animal
T1-diabetic 1
T1-diabetic 2
T1-diabetic 3
T1-diabetic 4
T1-diabetic 5
group average (animals)

Glucose conc.
600
599
600
600
600

599.80

Mice used for experiments in Chapter 5
Strychnine application T1-diabetic
Date of experiment
Cell
11/16/2012
4
11/21/2012
2
2/25/2013
1
7/23/2013
4
group average (cells)
group average (animals)

Glucose conc.
335
600
490
470
473.75
473.75

Glycine Transport Inhibitors T1-diabetic
Date of experiment
Cell
9/27/2012
3
9/27/2012
2
9/25/2012
3
group average (cells)
group average (animals)

Glucose conc.
528
528
600
552.00
564.00
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